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SUMMARY
TR6, also named DcR3, M68, is a recently identified soluble receptor belonging to the
TNFR superfamily. FasL, LIGHT and TL1 are 3 so-far identified ligands for TR6, and
they all belong to the TNF ligand superfamily. TR6 can interfere with fasL and Fas
interaction. It can also interfere with the interaction between LIGHT and HveA, and
between TL1 and DR3. Some tumors have high TR6 expression. It has been
hypothesized that TR6-secreting tumors use this molecule to evade immune surveillance
and gain survival advantage.
In this project, the role of TR6 in immune regulation was invcstigated. We demonstrated
that hurnan TR6 could cross-react with mouse LIGHT. As the mouse counterpart of TR6
unlikely exists according to Genebank search, this finding allowed us to use human TR6
in the mouse system. In the mouse system, soluble human TR6 could suppress IL-2, IL-5
and GM-CSF secretion by mitogen-activated T ceils, and downregulate cytotoxic T-cell
development in vitro. In vivo, soluble TR6 could suppress graft versus host disease and
allograft rejection. These effects of TR6 are probably achieved by its interference with
the interaction between LIGHT and HveA on T cells.
In human system, we found that solid phase TR6, in the presence of suboptimal solid
phase anti-CD3, could significantly costimulate T cells in terms of proliferation.
Blocking studies using soluble LIGHT and Fas indicated that LIGHT likely mediated the
costimulation. This bas revealed a novel mechanism of TR6 triggered reverse signaling
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through a ligand, LIGHT. Base on this finding, it is likely that the suppressive effect of
soluble TR6 in the mouse system is due to its interference of the two-way costimulation
between HveA and LIGHT. Intriguingly, soluble TR6 could augment T-cell proliferation,
lymphokine production and cytotoxic T-cell activity in the human system. The opposite
effect of soluble TR6 in the human and mouse systems is probably due to different
affinity of TR6 to human and mouse LIGHT. The dimeric TR6-Fc might have higher
afflnity to human LIGHT, hence capable of triggering strong reverse costimulation
through LIGHT. Although it rnight block the two-way costimulation between HveA and
LIGHT and abate the immune response, the overall effect is dominated by reverse
costimulation through LIGHT. In the mouse system, affinity of human TR6 to mouse
LIGHT might be lower, and cannot effectively trigger LIGHT reverse signaling; its
overali effect is thus biased to the blocking of the two-way interaction between HveA and
LIGHT, hence repressed immune responses.
We also found that human peripheral blood mononuclear cells could secrete TR6 and the
secretion was enhanced by T-cell activation. Interestingly, both soluble and solid phase
TR6 was able to suppress mitogen-induced T-cell aggregation. T cells pretreated with
TR6 had reduced actin polymerization and pseudopodium formation, which are both
important for the celi-celi interaction. These results suggest that TR6 might regulate the
duration of T-cell interaction with other cells, and allow T cells to disengage from
antigen presenting cells or fellow T ceils once the interaction becornes unnecessary.
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This study has discovered three important functions of TR6 in immune regulation. Some
of the findings, such as the suppressive effect of soluble TR6 in immune response and
enhancing effect of solid phase TR6 could be exploited for clinical applications. Our
findings have also broadened our knowÏedge on TR6 in immune regulation.
Key words: TR6/DcR3; LIGHT; reverse signaling; costimulation
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Résumé
Récemment, TR6 aussi connu sous le nom de DcR3 ou M68, a été identifié comme un
récepteur soluble appartenant à la superfamille du récepteur TNf. Les ligands FASL,
LIGHT et TL1, qui font partie de la superfamille du ligand TNF, ont la capacité de lier le
récepteur TR6. TR6 peut interférer au niveau de l’interaction de Fas et FasL, de LIGHT et
HveA ou encore de TL1 et DR3. Puisque certaines tumeurs expriment fortement le
récepteur TR6, il a été proposé que les tumeurs sécrétant TR6 pourraient échapper à la
surveillance du système immunitaire, par un avantage de croissance.
Ce projet explore le rôle du récepteur TR6 dans la régulation immunitaire. Nous avons
démontré que le récepteur TR6 humain peut interagir avec le ligand LIGHT de souris.
Cette observation nous a permis d’utiliser le récepteur TR6 humain dans un modèle de
souris, puisque l’équivalent murin de TR6 n’existe pas selon les recherches effectuées à
partir de Genebank. Chez le modèle murin, le récepteur humain TR6 soluble peut inhiber
la sécrétion de IL-2, IL-5 et GM-CSF produite par les cellules T activées et régule
négativement le développement des cellules T cytotoxiques in vitro. In vivo, le récepteur
TR6 soluble peut supprimer la présence de greffes en favorisant le développement de
maladies auto-immunes et le rejet des allogreffes. Ces effets biologiques associés à TR6
sont probablement initiés par l’interférence de TR6 dans l’interaction de LIGHT et HveA
dans les cellules T.
Chez un modèle humain, nous avons trouvé qu’en présence d’une concentration
suboptimale de la phase solide d’un anti-CD3, la phase solide de TR6 costimule
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significativement la prolifération des cellules T. Des études d’inhibition impliquant le
ligand LIGHT soluble et Fas indiquent que LIGHT est responsable de la costimulation.
Ceci suggère un nouveau mécanisme impliquant une inversion de la signalisation liée à
l’activation de TR6 par le ligand LIGHT. Basé sur cette observation, l’effet suppresseur
du récepteur TR6 soluble dans le modèle de souris est dû à l’interférence de la
costimulation à deux sens entre HveA et LIGHT. Étonnamment, le récepteur TR6 soluble
peut augmenter la prolifération des cellules T, la production de lymphokine et l’activité
des cellules T cytotoxiques dans le modèle humain. L’effet opposé du récepteur soluble
TR6 dans le modèle de souris et humain est probablement le résultat d’une différence
d’affinité de TR6 pour le LIGHT humain et le LIGHT murin. Le dimère TR6-Fc pourrait
avoir une plus grande affinité pour le LIGHT humain, d’où sa capacité à déclencher une
forte costimulation inversée induite par LIGHT. Dans le modèle de souris, l’affinité du
TR6 humain pour le LIGHT murin pourrait être plus faible et, par conséquent, incapable
de déclencher efficacement la signalisation inversée. Cet effet est alors biaisé par
l’inhibition de l’interaction à deux sens de HveA et LIGHT, d’où la répression de la
réponse immunitaire.
Nous avons également trouvé que les cellules mononucléaires du sang périphérique
peuvent sécréter le récepteur TR6, sécrétion qui serait augmentée après une activation des
cellules T. De façon intéressante, les phases soluble et solide de TR6 sont capables
d’inhiber l’agrégation des cellules T activées. Les cellules T pré-traitées avec TR6 ont une
réduction de la polymérisation de l’actine ainsi qu’une diminution de la formation des
pseudopodes, toutes deux importantes pour les interactions cellules-cellules. Ces résultats
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suggèrent que TR6 régule la durée des interactions des cellules T avec les autres cellules,
conduisant à un désengagement des cellules présentatrices d’antigènes ou des autres
cellules T, une fois les interactions devenues non essentielles. Cette étude a permis la
découverte de trois fonctions importantes du récepteur TR6 dans la régulation
immunitaire. Certaines de ces découvertes, telles que l’effet inhibiteur du récepteur TR6
soluble dans la réponse immunitaire ainsi qu’une augmentation de l’effet du TR6 de la
phase solide, pourraient être exploitées pour des applications cliniques. Nos observations
ont également permis d’élargir nos connaissances sur le rôle du récepteur TR6 dans la
régulation immunitaire.
Mots clé: TR6/DcR3; LIGHT; reverse signaling; costimulation
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I. INTRODUCTION
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I. INTRODUCTION
Cytokines are important glycoprotein messenger molecules capable of transmitting
signais from one ce!! to another. Most cytokines exist in secreted forrn but some are
either expressed at the celi surface or stored in the extra-cellu!ar space. To date more than
200 cytokines have been identified including interieukins, growth factors, chemokines,
interferons, and a host of others (Caliard et al., 1999; Locksley et aÏ, 2001). Cytokines
need to interact with their receptors expressed on the surface of the target ce!!s, thereby
triggering compiex interceliuiar signaiing cascades, which u!timateÏy control gene
expression required for the cellular response. Under normal circumstances, the
production of cytokines and the expression of their receptors are under tight and complex
biologicai contro!, including negative and positive feedback by the cytokines themselves.
Cytokines can be divided into severai groups such as the hematopoietins, the interferons,
the tumor necrosis factor (TNF)-related molecules, the immtmoglobulin (1g) superfamily
members, and the chemokines. Among these groups, the TNF superfamily is unique since
members of this superfarnily are mainly concentrated in the immune system and display
cruciai functional roles in regulating immune responses (Gruss and Dower, 1995; Gruss
et aÏ., 1996).
1.1. TNF and TNf receptor supeifaindies
TNF ligand superfamiiy was originated from two proteins, TNf-aipha (TNF Œ) and
lymphotoxin a (LT a). These two stmcturaiiy and functionaliy reiated but distinct
proteins, identified by the property of tumor celi lysis, were the prototypic members of
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the TNF superfamily (Carswell et al., 1975; Gray et al., 1984, Pennica et al., 1985). The
receptors ofTNf Œ are TNFR-I (p55) and TNFR-ll (p75) whereas the receptors for LTa
are TNFR-I, TNFR-II and HVEM/TR2 (Locksley et al., 2001). These receptors then
constituted a new TNF receptor (TNFR) related gene famity (Gntss and Dower, 1995;
Locksley et al., 2001). Both TNFR and TNF ligand superfamilies have experienced rapid
expansion over the past decade ami many molecules were identified as TNf or TNFR
superfamily proteins ($FPs) (Srnith et aï., 1994; Idriss and Naismith, 2000; Locksley et
al., 2001).
for the past decades there was no well-coordinated, systernatic naming system and the
nomenclatures for SFPs in these two superfamilies were complicated and sornewhat
redundant. It was common that some members had multiple names given by different
groups (as presented in Table 1 and Table 2). Based on this situation, a standard, official
designation system was foniially introduced for both TNF ligand and TNFR SFPs while
sorne popular, well-accepted narnes are still being used in parallel (Locksley et al., 2001).
(Details refer to Table 1 for related receptors and Table 2 for related Iigands).
1.2. TNfRJainily
Cunently, this stiil growing family has incorporated more than 20 different membrane
proteins and several open viral reading frames encoding related molecules (Locksley et
aÏ., 2001; Adams et al., 2002). As summarized in Table 1, the mammalian TNTR
superfamily now includes: TNFR-I, TNFR-II, Fas, 0X40, CD4O, CD27, CD3O, 4-133,
DcR1, DcR2, TR6 (DcR3), OPG, DR3, DR4, DR5, DR6, HVEM (TR2), RANK, TACI,
BAFFR, EDAR, 3CM, RELT, SOBa, Tnfthl, TAI (Armitage, 1994; Smith, 1994;
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Anderson et al., 1997; Ashkenazi and Dixit, 1998; Gruss and Dower, 1995; Locksley et
aï., 2001). Some rnost recent identified members such as 3CM, RELT, SOBa, Tnfrhl
and TAJ are currently stili flot well defined (Locksley et al., 2001). The viral open
reading frames encoding soluble TNFRs such as crmB (Hu et al., 1994), Va53 (Smith et
al., 1990) G4RG (Howard et ctl., 1991), and SfV-T2 (Upton et al., 1987) were also
identified.
1.2.1. The structzcraÏfeatures ofthe TNFR supe,famiÏy
The mammalian TNFR family members are type I membrane proteins, whose
extracellular N terminal part contains ligand-binding domain. A remarkable feature for
TNFR superfarnily is the low degree of sequence homology in their extracellular ligand
binding domain (20-25%) (Gniss and Dower, 1995). These SFPs are mostÏy trirneric
(Gruss and Dower, 1995; Armitage et al., 1994; Aggarwal et al., 1996; Bazzoni and
Beutler, 1996).
The definition of the TNFR superfarnily is mainly based on the conserved motif of
“cysteine-rich repeats” in the extracellular N-terminal region. These common conserved
cysteine-rich domains are also terrned as cysteine—rich motif or cysteine-rich domain
(CRD), which consists of multiple cysteine-rich repeats of approxirnately 30-40 amino
acids (Smith, 1994). In general, each member of this family contains varying numbers (2-
6) of CRDs as shown in Figure 1. Each CRD is featured by the presence of
approximately 6 cysteine residues that are interspersed within CRD domain. The
structure of CRD is supported by 3 intrachain disulfide bonds fonried by these 6 highly
conserved cysteines (Smith et al., 1994). These multiple cysteine-rich domains in the
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figure 1. Structural features of TNF receptors. There are two structural domains for
common TNF receptors. The cysteine nch domains (CRD) O) are located in the extra
cellular N-terminal portion. Several receptors aso have a death domain (DD) ( O)
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extracellular part have been shown to be involved in ligand binding (Locksley et al.,
2001).
The extracellular structure of TNFR SfPs can be best illustrated by TNFR and DR5.
These two receptors have been well studied for their crystal structure, which represents
common structural features of ail TNFR SFPs (Naismith et al., 1996; Hyrnoowitz et al.,
1999). for example, DR5 forms an extended rod-like shape consisting of 3 CRDs which
form the interface to bind its cognate ligand(s). DR5 had a total of 7 disulfide bridges: 6
are in CRD 2 and CRD3 (three for each) and I in C-terminal part. These disulfide bonds
form a structural scaffold and two patches formed are located there for ligand binding.
The combination of structural conservation and variable arnino acid sequences in the
ligand contacting region confer the ligand-binding specificity. Notably, the structure of
TNFR is rather flexible and can be optimized for its interaction with ligand through a
series ofhinging movements (Idriss and Naisrnith, 2000).
In addition to the membrane-bound form, many TNF receptors also exist in a soluble
form. These soluble molecules are, in many cases, generated by proteolytic cleavage of
ceil surface receptors. Soluble TNTR-I, TNFR-II, CD27, CD3O, CD4O, and fas are ail
generated in this fashion (Gruss and Dower, 1995). The only exception is 4-1BB, whose
soluble form is generated by alternative splicing (Grnss and Dower, 1995). The necessity
of the soluble forms of these receptors is not fully understood.
1.2.2. The biologicalfeatures of TNfR superfamity
The TNFR SFPs have emerged as prominent regulators of the immune system (Tracey
and Cerami, 1994). In the immune system, TNFR SfPs are well known for their critical
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roles in regulating immune responses such as celi activation, proliferation, differentiation,
apoptosis, immunoglobulin (1g) class switching, immune evasion, and immune
suppression (Smith et al., 1994; Aggarwai et al., 1996; Tewari and Dixit, 1996; Baker et
al., 1996; Locksley et al., 2001). Sorne SFPs are also involved in the generation and
developrnent of iymphoid organs (Matsumoto et aï., 1997).
The primary feature of TNFR superfamily members is ce!! death induction including
tumor killing and this effect was observed severa! decades ago (Carswell et al., 1975).
Many, if not ail, TNFR members are related to ce!! death induction. Members such as
TNF, Lia, CD3OL, CD95L, 4-1BBL are a!! capable of inducing cytotoxic ce!! death
(Gruss et al., 1996; Gruss and Dower, 1995). Probably this ability to induce ceil death is
one of the unique features with remarkab!e adaptive va!ue that TNT/TNFR SFPs have
developed (Gniss and Dower, 1995; Locksley et al., 2001). As will be detailed in the
next section, severa! TNF receptors contain a structure called “death domain” which is
responsible for ceil death induction and these receptors are termed “death receptors”
(DR). There are 8 receptors containing “death domain” in TNFR superfarni!y and at least
6 of them can induce apoptosis through activation of caspases (Screaton and Xu, 2000;
Raff, 1998). Meanwhile, other TNF/TNFR SFPs lacking death domains can potentially
modulate the response to DRs or directly influence ce!! deathlsurvival. for instance,
TNFR-II markedly enhances TNFR-I induced T celi death and CD4O can augment Fas
induced B celi death (Garrone et al., 1995; Chan et al., 2000b).
In contrast to the death induction feature of TNFR SFPs, it is interesting that they are also
closely related to !ymphocyte survival including T/B celi proliferation and differentiation
(Locks!ey et al., 2001). Indeed, the major docurnented function of TNFR SfPs is
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associated with lymphocyte survival. For instance, Blys (officiai symbol: TNFSFI3B, or
THANK, BAFF, see Table 2) expressed on activated dendritic celis can interact with the
TACI and BCMA receptors (both are TNFR members, see Table 1) on B ceils and
promote B ceil survival (Laabi and Stresser, 2000, Moore et al., 1999). Similarly, T ceil
activation is also regulated by TNF/TNFR SFPs. For instance, LT3R enhances T celi
activation and promotes T celi clone expansion by engaging with its ligand LIGHT
(Tamada et aÏ., 2002). Some other members such as CD4O and Fas may also stirnulate T
cell survival and proliferation by engaging with their receptors (Cayabyab et aÏ., 1994;
Suzuki et al., 199$).
In addition to modulating lymphocyte deathlsurvival, SFPs of this superfamily are also
associated with antigen presenting celis (APC) survival and maturation. For instance,
dendritic celis (DCs) are potent APCs for antigen presentation but fully differentiated and
mature DCs wilÏ undergo rapid apoptosis. The life span of mature DCs can be prolonged
substantially by TNF SFPs such as CD4OL, TNF, TRANCE (TNF related activation
induced cytokine) and recently identified member LIGHT (Wong et al., 1997; Tamada et
al., 2002).
Some, if not most, TNFR SfPs are involved in T celi costimulation. For example, both
TNFRJ and Fas can co-stimulate T celi activation under diffei-ent settings (Siegel et al.,
2000; Suzuki et aï., 2000A, 2000B). In addition, the SFPs such as 0X40, CD27, and 4-
1BB regulate the activation and expansion of CD4+ and CD$+ T celis responding to
dendritic ceils beanng their respective ligands. Costimulation effects were also observed
for LTR/LIGHT pair. It was found most likely that this pair provides costimulation for
T ceil activation and plays a critical role in T celi activation independent of B7/CD2$
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costimulation pathway (Tamada et al., 2000; Wang et al., 2001). Thus, it is suggested
that TNFR SFPs might be critically important in negative selection and determine the
activation and/or apoptosis of T celis (Sebzda et al., 1999; Wang et al., 2001).
Another welI-docurnented function of TNFR superfamily is to orchestrate permanent
lymphoid organ structure. A remarkable example is LTf3R that belongs to TNFR
superfamily and plays critical roles in the immune system. Several studies showed that
LTJ3W’ mice lacked lymph nodes (LN) and Peyer’s patch (PP) and displayed severe
disorganization of spienic architecture, featured by the absence of T/B celi segregation,
marginal zones, follicular dendritic ccli (FDC) networks, and germinal centers (GC) (De
Togni et al., 1994; Banks et al., 1995; Wu et al., 1999). Depletion ofRANK or RANKL
lead to the disappearance of ail peripheral and mesenteric lymph nodes while Peyer’s
patches remain intact and the spienic architecture is unaffected (Kim et al., 2000; Kong et
al., 1999; Dougall et al., 1999). Studies dernonstrated that the requirements for
RANX/RANKL and LTalj32 or LTR do flot compensate for each other. Ail these data
suggest that SFPs of TNFR superfamily are necessary for the formation and development
of lymphoid immune organs, sorne of them being indispensable.
In addition to critical functions in the immune system, other functions were also
identified for TNfR SFPs. For instance, Edar is a death domain containing protein and
recent studies indicate that this protein is important in the development of hair, teeth and
other ectodermal derivatives (Headon et al., 2001).
1.2.3. Subsets oJTNFR superfainiÏy
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Based on their structural and biological features, the TNFR sttperfarnily SFPs can be
further divided into different groups according to the presence of featured domains in the
intracellular portion of the receptor. The SFPs in the first group featured by a TNfR
associated factor (TRAF) binding domain that enabies coupling to TRAFs, that in tum
activate a signaling cascade that resuits in the activation of Nf-KB and initiation of
transcription (Rothe et ctÏ., 1995; Wallach et aÏ., 1999). The second group ofreceptors is
featured by a 60- amino acid globular structure named “death dornain” (DD) and these
death dornain-containing receptors are termed as death receptors (DRs) (Tartaglia et aï.,
1993; Itoh and Nagata 1993). The third group bas drawn more attention recentiy and
members of this group are designated as decoy receptors (DcRs) that include DcR1,
DcR2, DcR3/TR6 and OPG (Ashkenazi and Dixit, 1999). Ail members in this group
except DcR2 do not have cytoplasmic domain and thus they may act as inhibitors and
compete with other signal-transducing receptors for ligand binding (Ashkenazi and Dixit,
1999; Ashkenazi, 2002).
1.2.3.1. TRAf associated subgrottp
The TRAFs are adaptor ptoteins belonging to ring and zinc-linger proteins. The members
ofthis group are TNFRII, CD4O, CD3O, CD27, LTF3R, 4-YBB, 0X40, NGFR, HVEM,
GITR and RANK (as presented in Table 1). They bind directly to the receptor’s
cytoplasmic tau. They also bind to one another in homotypic and/or heterotypic
interactions. They are believed to convey certain signais in proliferative and pro
inflammatory responses. This is achieved, in large part, by activation of NF-KB, a
transcription factor involved in nurnerous proliferative and pro-inflarnmatory events
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(Jabara et al., 2002; Wallach et al., 1999; Harrop et al., 199$). So far at least 6 TRAFs
have been found to associate with non-DD TNF receptors (Locksley et aï., 2001). Most
TNFR SFPs have no death domains but contain a consensus motif which is capable of
binding to the TRAF proteins (Ye et al., 1999).
1.2.3.2. Death receptor subgroup
The above mentioned “death dornain” was first coined from studies of deletion
mutagenesis involving TNFR-I rnediated apoptotic celi death (Tartaglia et al., 1993).
The proteins harboring “death domains” were thus defined as death receptors (DRs) and
they form DR group within the TNFR superfamily (Ashkenazi and Dixit, 1999; Locksley
et aï., 2001). This death-domain-containing receptor subgroup now includes up to $
members: TNF-R1, Fas, and recently discovered DR3 (Chiimaiyan et al., 1996; Marsters
et al., 1996; Kitson et al., 1996; Bodmer et al., 1997; Screaton et al., 1997), DR4 (Pan et
aï., 1997), DR5 (Pan et al., 1997) and DR6 (Pan et al., 1998), EDAR (lucher et al.,
2000) and NGFR (Gruss, 1996). The typical conserved death dornain (DD) is a 6$ amino
acid segment located within the cytoplasmic region of the receptor. Upon ligation with
either cognate ligands or specific agonistic antibodies, death receptors can activate an
apoptotic signaling pathway (Nagata, 1997).
These death receptors have common structural features such as 2-6 CRDs in their
extracellular domains and an intracellular death domain. The death domain most likely
functions as a protein interaction dornain and provides docking sites for signaling
molecules, therefore enabling each receptor to couple to the caspase cascades which are
critical for the induction ofapoptosis.
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1.2.3.3. Decoy receptor subgroup
Another subgroup of the TNFR superfamily was termed “decoy molecule”. This decoy
receptor subgroup now includes DcR1 (decoy receptor 1, also known as TRID or TRAIL
R3) (Pan et al., 1997; Degi-Esposti et al., 1997; Sheridan et al., 1997; Pitti et al., 1998),
DcR2 (decoy receptor 2, also known as TRUNDD or TRAIL-R4) (Pan et al., 1998;
Degli-Esposti et al., 1997), DcR3 (TR6) (Pitti et al., 1999) and osteoprotegerin (OPG)
(Simonet et aÏ., 1997; Ashkenazi and Dixit, 1999). DcR1 and DcR2 are ceil surface
proteins whereas DcR3 and OPG are soluble molecules. Both DcR1 and DcR2 bind to
TRAIL with a similar affinity (Pan et al., 1997A; Pan et al., 1997B; Sheridan et al.,
1997). DcR1 is a glycosylphosphatidylinositol (GPI)-linked protein without an
intracellular death domain whereas DcR2 is a transmembrane receptor but with a partially
deleted death domain and accordingly, both are incapable of transmitting apoptotic
signais (Ashkenazi and dixit 1999; Deli-Esposti et al., 1999). The product of OPG is a
secreted protein that also binds to TRAIL but with much weaker affinity compared with
other receptors. DcR3 (TR6), as will be described in details below, is doser to OPG and
exists as a secreted protein (Pitti et al., 1998).
Both DcR1 and DcR2 are believed mainly to function as anti-apoptotic decoy receptors
that compete with DR4 and DR5 for TRAIL binding and consequently protect those
receptor-bearing ceils from TRAIL-induced apoptosis (Ashkenazi and dixit, 1998; Deli
Esposti et aÏ., 1999). DcR1 is a GPI-linked protein and its role in active signal
transduction has flot been fully eÏucidated. Ernerging evidence suggests that DcR2 may
be involved in activating signal transduction since it lias been shown to activate NF-icB in
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some systems (Degli-Esposti et al., 1997). In contrast, there are reports of failure of
DcR2 to activate Nf-KB in certain systems (Meng, 2000). Thus more studies are
necessary to explore the role of DcR1 and DcR2 in anti-apoptosis signal transduction and
in apoptosis.
1.2.3.4. General characteristics of TR 6
TR6 is a nove! TNF decoy receptor with the officiai designation of TNFR$F6B (see
Table 1). By screening expressed sequence tagged (EST) database, Pitti (1998) identified
a previously unknown fu!I-!ength cDNA from a human fetal lung library. This cDNA
showed homology to other TNFR superfamily members. The protein encoded by this
gene was then named decoy receptor 3 (DcR 3) (Pitti et ctl., 199$). This gene was also
independently identified by other groups and named TR6 (Yu et al., 1999) or M6$ (Bai et
al., 2000), respectively. The hurnan TR6 gene is mapped at position 20q13.3 (Pitti et al.,
199$), whi!st its mouse counterpart might not exist since a BLAST search of the mouse
genome did not reveal sequences with any significant homology. Since the position of
20q 13 is also named “cancer amplicon” where genes responsible for rnany types of
tumors are !ocated, TR6 may be a candidate gene associated with certain types of
malignancy (Kom et aÏ., 1999; Medeiros et aï., 1999; Stubbs et al., 1999; Savelieva et
al., 1997;Sonoda et aÏ., 1997; Sakakura et aï., 1999).
The fuIl-Iength open reading frame ofTR6 encodes 300 amino acid residues with the first
29 amino acid residues as signal sequence. The mature fonri ofTR6 has 271 amino acid
residues with no transmembrane region. There is only one potential N-!inked
glycosylation site at Asn-173. Like OPG, TR6 vas regarded as a soluble secreted protein.
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TR6 shares remarkable amino acid sequence homology with OPG (31%) and TNFR-II
(29%) but less liomology with Fas (17%) (Pitti et al., 1998). TR6 was reported to have
two complete and two incomplete cysteine-rich motifs, which is the hallmark of TNF
receptors.
The TR6 mRNA lias prorninent expression in lung and colon cancers, whereas it is
weakly detectable in several hematopoietic celi unes, and is hardly detectabÏe in many
tissue samples (Pitti et al., 199$). In the immune system, TR6 is highly expressed in both
lymph nodes and spleen, but the expression in thymus is weak (Pitti et al., 199$; Bai et
al., 2000). In addition, TR6 is expressed in an endothelial celi une and its expression is
inducible by phorbol 12-myristate 13-acetate (PMA) /ionomycin in Jurkat T leukernia
celis (Yu et al., 1999). Moreover, TR6 mRNA over-expression was reported in
gastrointestinal cancers but without gene amplification (Bai et al., 2000). Also, the
expression of TR6 can be detected in malignant glioma ceils as well as in human
glioblastomas. In addition to human tumors, the TR6 gene is also over-expressed in
silicosis or systemic lupus patients (Otsuki et aÏ., 2000).
Mild et al. investigated a large number of colorectal cancers and found nearly 63% (185
out of 294) of patients with DcR3 gene amplification (Mild et al., 2002). In another
study, it was found that TR6 was amplified and over expressed in EB virus- and human T
celi leukemia virus-I— associated lymphomas (Ohshima et aÏ., 2000). This expression
trend is also true at the protein level of TR6. For instance, TR6 protein was found over
expressed in human adenocarcinomas of the esophagus, stomach, colon, and rectum
while no gene amplification was detected (Bai et al., 2000). It was reported recently that
up to 73% (163 out of 223 patients) of colorectal patients showed up-regulated TR6
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protein level (Mild et aÏ., 2002). These data suggested that certain types of turnor as welÏ
as EBV and human T ce!! leukemia virus-1 may use TR6 to escape from immune
surveillance during lymphomagencsis, or that virus infected Ïymphoma ceils with TR6
expression might be selected during multi-step tumorigenesis (Ohshima et al., 2000).
Recent studies in our laboratory as well as in others suggested that TR6 over-expression
correlates with the grade of malignancy and could be used as diagnostic and prognostic
parameter (Wu et al., 2003; Roth et al., 2001).
1.2.3.5. The TR6 Ligands
The FasL (Fas ligand) was the first ligand identified for TR6 (Pitti et aï., 199$). FasL is
one ofthe major effectors ofcytotoxic T lymphocytes (CIL) and natural killer (NK) cells
and a major inducer of apoptosis. It is also involved in the establishment of peripheral
tolerance in the activation-induced celi death of lymphocytes (Zhang et al., 2000; Ju et
al., 1999). Moreover, the expression ofFasL in non-lymphoid and tumor cells contributes
to their maintenance (Nagata, 1997). LIGHT (also termed HVEM-L) is another cognate
ligand for TR6 (Yu et al., 1999). Very recently, another novel member of TNF ligand
superfamily TLÏA was found to be a third ligand for TR6 (Migone et aï., 2002). TL1A is
considered as the longer variant ofTLl and this molecule was designated as VEGI when
it was identified in endothelial ce!! DNA libraries (Zhai et al., 199$; Yue et al., 1999).
Studies at the mRNA level show that TLÏA is highly expressed in endothelial cells and is
inducible by TNF and IL-1. TL1A is the ligand for both DR3 and TR6 (Migone et al.,
2002). DR3 is a TNFR member and has the capability of inducing NF-icB activation and
apoptosis upon over-expression. DR3 shares another ligand TWEAK (or Apo3L) with a
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novel receptor TWEAK (Masters et aï., 1998; Wiley et ctl., 2001). But the relationship
between these proteins and the significance of their interactions have yet to be fully
studied
1.2.3.6. The identfled biotogicalfimctioizs oJTR6
It has been demonstrated that TR6 could neutralize the biologicai effects of FasL by
inhibiting fas-FasL interaction (Pitti et al., 1998). This decoy receptor substantialiy
biocks the FasL-induced apoptosis in Jurkat ceils as well as FasL-dependant NK celi
activity (Comol1y et al., 2001). These resuits suggest that TR6 could interact with FasL
under certain conditions and modulate immune responses, especially apoptosis mediated
by the Fas/FasL pathway.
TR6 can suppress LIGHT binding to both LTR and TR2 (Yu et al., 1999; Mauri et al.,
1998), and it is conceivable that such interference can inhibit LTf3R- and TR2-mediated
responses in immune ceils. It was demonstrated that TR6 can interact with LIGHT and
thus inhibit LIGHT —mediated cytotoxicity of H29 ceils. These resuits suggest that TR6
acts as a natural inhibitor of LIGHT mediated tumor celi killing.
In addition to modulation of immune responses, it was found in a recent study that TR6
profoundly modulates dendritic ceils LDCs) differentiation and maturation from CD14
monocytes (Hsu et al., 2002). Interestingly, it was reported that TR6 enhances
CD86/37.2 expression, whereas CD8O/B7.1, CD4O, CD54/ICAM-1, CDY.a and HLA
DR were ail repressed. In addition, DcR3-treated DCs dramatically enhanced 1L4
secretion by naïve T celis (CD4CD45RA), thus favoring Th2 dcvelopment.
The ligand TL1A can also function as a T ceil costimulator. The T ccli stimulation
induced by TL1A resuÏts in an increased responsiveness to IL-2 and other pro-
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inflammatory cytokines (Migone et al., 2002). TR6 competes with DR3 for TL1A
binding with similar affinity. Therefore, it is possible that TR6 may modulate the
duration and magnitude of immune responses mediated by DR3. Moreover, since DR3
can induce apoptosis, blocking the interaction between TL1A and DR3 by TR6 might
provide protection from apoptosis to certain types oftumors (Migone et al., 2002).
1.2.4. The other TNF receptors related with TR6
Obviously, TR6 may have important functions stili to be elucidated in cancer
development and in the immune system. In the latter, TR6 might compete with other TNf
receptors for core common ligands such as LIGHT and FasL and thus interfere with their
biological functions. Among all the possible TNFR SFPs that share LIGHT and FasL
with TR6, TR2 and Fas are predominantly expressed in the immune system and are
critically important in regulating immune responses. As such, to decipher the nature of
TR6, identify with which ligand TR6 interacts and the related receptor(s) such as TR2
and Fas will certainly help to better understand the underlying mechanisrns of the
regulatory roles of TR6 both in vitro and in vivo.
1.2.4.1. HVEM/TR2
The receptor herpes virus entry mediator (HVEM or TR2) is a recently discovered TNFR
superfamily member with broad tissue and cell type expression especially in the immune
system (Montgomery et cd., 1996; Kwon et al., 1997; Tan et aÏ., 1997). This molecule
was also identified by screening expressed sequence tag (EST) cDNA database for
sequence hornology with cysteine-rich motifs of the TNFR superfamily (Harrop et al.,
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1998). This molecule was discovered through its ability to mediate HSV infection. The
TR2 gene locates at chromosome lp36, a position close to other TNFR members such as
CD3O, 4-1BB, OX-40, and TNfR-II (Montgomery et al., 1996). Three ligands so far
have been defined for TR2: the HSV surface envelope glycoprotein gD, lymphotoxin a
(LT a) and the newly described TNF ligand family member LIGHT (Montgomery et al.,
1996; Mauri et aÏ., 1998).
The TR2 mRNA can be readily detected in lung, spleen, thymus, monocytes, dendritic
ceils, B and T lymphocytes, but not in liver, brain, and skeletal muscle (Morel et al.,
2000). Moreover, RNA analysis unveiled that most solid tumor unes do flot express TR2.
On the other hand, some hematopoietic celi lines do express TR2 (Kwon et al., 1997).
The full-length TR2 encodes a 283 amino acid protein. It is a type I transmembrane
protein containing a 50-amino acid cytoplasmic region without a death domain (Harrop et
al., 199$). At the protein level, expression studies indicated that TR2 protein has wide
distribution and can be readily detected by flow cytometric analysis in peripheral blood T
and B lymphocytes, NK ceils, and monocytes (Mord et al., 2000). Interestingly, it was
reported in a recent study that TR2 and one of its ligands LIGHT display reciprocal
expression at T ceil surfaces as detected by flow cytometric analysis (Mord et al., 2000).
LIGHT is hardly detectable in resting T celis, but its expression was enhanced tipon
activation (Morel et al., 2000). On the other hand, HVEM showed down-regulation upon
T ceil activation. Data from confocal microscopy and intracellular staining by flow
cytometry showed the existence of intracellular LIGHT in unprimed T ceils. After
activation, there is a pronounced induction of LIGHT both intracellularly and at the cell
surface. This suggests that de novo synthesis and redistribution of LIGHT both contribute
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to the enhancement of LIGHT expression at ceil surface. The detailed mechanism of
down-regulation of TR2 expression by LIGHT is stiil flot well understood.
The biological function of TR2 was an active area of investigation in the past few years.
Current evidence suggests that TR2 is closely associated with T ceil activation and a
number of T celi responses such as proliferation, cytokine production, and expression of
celi surface activation molecules (Hanop et al., 1998). LIGHT, as its ligand, stimulates
the proliferation of activated T ceils expressing TR2 (Harrop et aÏ., 1998), stimulates NF
iB activation, and induces apoptosis in celis expression both TR2 and LTR (Zhai et al.,
1998; Harrop et al., 1998). Recently, studies show that LIGHT can costimulate T celi
responses by interacting with TR2 (Kwon et al., 1997; Tamada et al., 2000A; Tamada et
al., 20003) and TR2 is critically important in T celi costimulation. T celi derived LIGHT
can readily deliver stimulation to TR2 on dendritic celis, that in tum up-regulate T ceil
activity (Shaikh et al., 2001). Moreover, TR2 on T cells can also receive LIGHT
stimulation directly from LIGHT expressing T ceils (Wang et al., 2001).
1.2.4.2. fas
Fas (also named APO-1 or CD95) is the primary receptor for fasL and this molecule is a
type I membrane protein belonging to the TNFR family (Suda et al., 1993). Fas is
abundantly expressed in various tissues and celi types (Suda et aÏ., 1993), especially
thymocytes, activated T cells and virus transformed T cells. Resting B cells do flot
express fas, but its expression can be induced by CD4O ligand or endotoxins (Briones et
al., 2002; Hahne et al., 1996). Fas has broad tissue distribution, but is most abundantly
expressed in the thymus, liver, heart and kidney (Itoh and Nagata, 1993). Cross-linking of
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL XIAOCHUN WAN 21
Fas by an agonistic antibody or ligation by FasL will cause Fas clustering which is
necessary for receptor activation and death signal initiation (Kischkel, 1995).
1.3. TNf Ïigand superfamiÏy
As listed in Table 2, the mammalian TNF ligand superfamily also exhibited rapid
expansion in recent years and it currentÏy includes TNF Œ, LTA (lymphotoxin-Œ) or LTB
(lymphotoxin—t3), FasL, CD27L, CD3OL, CD4OL, 4-1BBL (Gruss et al., 1995), TRAIL
(Wiley et al., 1995), TRANCE/RANKL/OPGL (Lacey et al., 1998), TWEAK
(Chicheportiche et al., 1997); APRIL/TALL-2 (Hahue et aï., 199$; Shu et al., 1999),
AITRL (Kwon et al., 1999), VEG1 (Zhai et al., 1999), BAFF/TALL1 (Shu et al., 1999;
Schneider et cii., 1999), LIGHT (Mauri et al.,1998), TRANCE (Wong et al., 1997),
TLI/VEGI (Zhai et ai., 1999), TL1A(Migone et al., 2002), TL6/hGITRL (Kwon et al.,
1999). AIl these ligands share, to some extent, structural features, which might be
important for their functions. Meanwhile, these ligands, in a mechanism similar to other
cytokines and growth factors, exert their effects through receptor-ligand interactions that
induce downstream signal transduction events (Gntss and Dower, 1995).
1.3.1. The structuralfeatures of TNf ligands
The members of TNF ligand superfamily are highly diverse in sequence and have an
average of 20% (range from 12% to 36%) sequence homology in their extracellular
domain. These ligands exist mainly in membrane-bound forms and their biologically
active forms are trimeric/multirneric complexes (Gruss and Dower, 1995). Their
monomers are composed oftwo stranded beta pleated sheets (Armitage et aÏ., 1994; Lotz
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et al., 1996). TNF ligands are synthesized as type II transmembrane proteins
characterized by their extracellular C—terminus. The typical TNF ligand structure consists
of a short cytoplasmic segment (10-80 amino acid residues) and a relatively long
extracellular region (140-215 amino acid residues). Several members of this superfamily
have rnoderate-sized cytoplasmic regions. The cytoplasmic regions of TNF tigands are
not conserved among farnity members, but highly conserved across species. This cross
species conservation implicates sorne important biological functions such as signal
transduction for the cytoplasmic region (Smith, 1993), as also demonstrated for OX4OL
and CD4OL (Stuber et al., 1995; van Essen et ctl., 1995).
1.3.2. The Soluble form ofTNFLigands
Although members of the TNF ligand superfamily norrnally exist as trimeric or
multimeric membrane bound proteins, many of them are also expressed and functional in
a soluble forrn. For example, Fas ligand (Suda et al., 1993; Tanaka et al., 1995), TNF a
(Kriegler et al., 1988), CD4OL (Graf et al., 1995), OX 40L (Stuber and Strober, 1996),
CD27L (Lens et al., 1998), 4-1BBL (Salih et al., 2001), LIGHT (Harrop et al., 1998),
TRAIL (Wajant et aÏ., 1995) were ail found to exist in soluble forrns that are biologically
active. The release of soluble ligands from the celi surface is mediated by proteolytic
cleavage and likely regulates receptor/ligand interactions between ceils. Cleavage of
membrane-bound ligand to an active soluble forrn would alter both proxirnal and distal
cellular responses, including celi survival and costimulatoiy or inflarnrnatory responses.
Currently the mechanism of coexistence of both forms is not fully understood.
Interestingly, studies on TNFŒ discovered that while membrane-bound and soluble forms
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are both biologically active, soluble TNFŒ is more potent than the membrane-bound form
(Decoster et aÏ., 1995).
Lymphotoxin—beta (LT-f3) is an exception to this feature. It onÏy exists as a membrane
bound form (Browning et al., 1996). Human LT-3 (also narned as p33) is a 33 kDa
glycoprotein cloned from T celi hybridorna celi une. On the celi surface, LT forms a
trimeric complex with TNF 3 in either LT Œ2f3 1 (major form) or LT al J32 (minor form)
ratio (Hochman et al., 1995).
1.3.3. The biologicalfeatures oJTNf Ïigands
The TNF ligand SFPs play multiple roles in both innate and adoptive immune responses
(Smith et al., 1994), obviously through their interaction with TNFR SFPs. One
fundamental feature of TNF ligand superfamily is the biological activity related to T-cell
mediated immunity (Suda et al., 1993; Armitage et aÏ., 1993)
The ability to induce celi death (either necrosis or apoptosis) is the most thoroughly
investigated feattire of TNT ligands as established for TNF, LTa, CD3OL, 4-1BBL and
FasL (Gray et aÏ., 1984; Smith et aÏ., 1993; Alderson et al., 1994; Suda et al., 1993; Liu
et al., 1989; Gruss et aÏ., 1994). TNF ligands are also directly involved in lymphoid organ
generation and development. For instance, mice genetically deficient for LTalf32 do flot
develop secondary organs such as lymph nodes, or Peyer’s patches, and have defective
spleen structure and humoral immunity (Fu and Chaplin, 1999). Among these TNF
ligands, LIGHT and FasL will be discussed in details for their biological functions.
Interestingly, these two ligands also have the capability of reverse signaling and receptor
function.
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1.3.4. Reverse signaling
The reverse signaling phenomenon had been observed several ycars ago and recent
studies have provided more evidence for TNFR famiiy members’ reverse signaling
capability (Hsu et al., 2002; Suzuki et al., 1998). Members such as CD3OL, CD4OL,
TRANCE, TRAIL and DR4 are reported to transmit reverse signais into ligand bearing
celis. The reverse signaling of these ligands has important biological functions. For
instance, reverse signaling through CD4OL is associated with different immune responses
such as T celi costimulation and germinal center formation (Rooney et al., 2000).
Moreover, CD4OL is able to trigger brief CD4 T celi activation as weli as regulatory
cytokine product secretion and apoptosis (Blair et al., 2000). Cross-linking OX-40L on
CD4OL-stimulated B ceils resuits in enhanced B celi proliferation and down-reguiation of
the transcription factor B ceil iineage-specific activator protein (BSAP) ÇStuber et al.,
1995). More studies showed that CD4OL reverse signaling ieads to T celi costimulation
(van Essen et al., 1995). In addition, CD4OL reverse signaling was associated witli
protein tyrosine phosphorylation, Ca 2+ influx, and activation ofLck, protein kinase C, c
jun N terminal kinase, and p38 mitogen-activated protein kinase activation in EL-4
thyrnoma ceils (Brenrier et al., 1997a, Brenner et ai., 1997b). In a recent report, it was
further demonstrated that maximal proliferation of CTL requires reverse signaling via
Fas-L (Suzuki and Fink, 1998). In addition, reverse signaling through CD27/CD7O has
been demonstrated to induce pronounced proliferation of a subset of leukemic B celis, an
effect that is synergisticaliy enhanced by ligation of CD4O (Lens et aÏ., 1999). In a more
recent report, Chen demonstrated that TRANCE enhanced IfN y production in activated
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1h ceils (Chen et al., 2001). CD3OL cross-linking activates neutrophils (Wily et al.,
1996) and inhibits 1g class switching in B ceils (Cerutti et al., 2000). Crosslinking of
TRANCE enhances IFN ‘ secretion by Thl celis (Chen et al., 2001). Crosslinking of
TRAIL induces p38 mitogen activated protein kinase activation (Chou et al., 2001).
Studies on CD40L reveal that reverse signaling associated with TRAIL cross-Iinking also
induces p38 mitogen activated protein kinase activation (Brenner et al., 1997A). Taken
together, these findings illustrate the importance of reverse signaling in immune system
activation. It would be interesting to know whether bi-directional signaling also cxists
with other members of the TNF superfarnily. For example, we investigated the reverse
signaling properties ofTR6 via its ligands.
1.3.5. fas ligand
The Fas ligand (FasL or CD95L) belongs to TNF ligand superfamily (Suda et aÏ., 1993).
fasL is expressed as a trirneric molecule either in membrane-bound or soluble fomi. FasL
is predominantly expressed in activated T celis and natural killer (NK) ceils and also
expressed constitutively at immune privileged sites (Nagata, 1997; Oshimi et al., 1996;
Suda et al., 1993). It is a type II membrane protein and its extracellular region consists of
a 150 amino acid stretch displaying remarkably low homologies (20-25%) with other
members ofthis family. The cytoplasmic region ofFasL has 77 amino acid residues.
FasL-triggered apoptosis is the fundarnental regulatory factor for cell survival and
maintenance of normal inm-iune functions, and dysregulation of this system has been
shown to resuit in many hurnan pathological conditions such as SLE (Wu et al., 1996).
Recently it was reported that DcR3 cornpetitively bind to FasL, and therefore block the
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fas/FasL engagement which ultimately resulted in the blockage of apoptosis (Pitti et al.,
1998).
The interaction of Fas-L with the extracellular ligand-binding dornain of the Fas receptor
can induce Fas trimerization and activate of the apoptotic celi death pathway. In addition,
the Fas/f as-L system plays a critical role in CIL activity and regulation of immune
response amplitude (Nagata, 1997). This Fas-L induced celi death utilized by CTL
system could be involved in the immune response against tumor celis and other cytotoxic
activities. The expression of FasL in the plasma membrane of numerous turnor ceils
allows them to kili Fas bearing immune celis in vitro (Nagata, 1997). These observations
have suggested that tumor celis may use FasL to induce a specific immune tolerance.
However, in the in vivo setting, FasL expression rather induces tumor celi rejection. The
quantity and the environment of FasL expressed on turnor celis could determine whether
tumor ceils are toÏerated or rejected (Suzuki et al., 2000)
1.3.6. LIGHT
LIGHT is a recently identified and characterized core member of TNF ligand
superfamily. The term “LIGHT” stands for “homologous to lymphotoxins, showing
inducible expression, and competing with HSV glycoprotein D for herpes virus entiy
mediator, a receptor expressed by T lymphocytes” (Mauri et al., 1998; Harrop et al.,
1998). The standardized symbol of LIGHT is TNFSF14 (refer to Table 2 and Lockslay et
aÏ., 2001). Since LIGHT can competitively block the engagement ofHSV glycoprotein D
to HVEM, it was also named HVEM ligand (HVEM-L) (Hanop et aï., 199$).
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The LIGHT gene maps on human chromosome 19, adj acent to other TNF ligands such as
CD27L, 4-1BBL (Granger et aÏ., 2001). The primary structure of LIGHT as predicted
from the cDNA sequence contains 240 amino acid residues, no predicted signal cleavage
site, and a stretch of 22 hydrophobic residues as a transmembrane region, characteristic
of a type 2 transmembrane protein. The extracellular dornain of LIGHT consists of a
short membrane extension of 39 arnino acid residues close to the receptor-binding
domain. There is only one N-linked glycosylation site identified for LIGHT that lies
within the major receptor-binding loop (A-A’Ç3 strand) (Harrop et al., 1998).
LIGHT is closely related to LTŒ and LTf3 according to amino acid sequence homologies
and shares receptor specificity but is genetically different. The similanty of LIGHT to
lymphotoxins outside the scaffold regions is reflected in the conservation of tyrosine 173
located in the D-E loop, a contacting region ofLTa for TNFR (Banner, 1993). Structural
study indicates that LIGHT has a secondary structure of anti-parallel 3 sandwich
conformation that favors the formation of a homotrimer structure.
Ibis is also suggested by sequence homology studies in the TNF ligand family (Rooney
et al., 2000B). Species conservation between human and mouse LIGHT is 76% (Mauri et
aÏ., 1998). LIGHT exhibits significant sequence homology with the C-terminal receptor
binding domains of LTf3 (34% identity), Fas ligand (30%), 4-1BB ligand (29%), TRAIL
(28%), LTa (27%), TNF (27%), and CD4OL (26%). No sequence homology is found
with HSV-1 envelope glycoprotein D. Sequence homology is mainly limited to residues
forming the J3 sandwich structure and assembling as a trimer.
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1.3.6.1. LIGHT expression cmd distribution
It was found that LIGHT mRNA was abundantly expressed in spleen and lymph nodes,
but weakly in peripheral blood, thymus, appendix, and in bone marrow as well. Visceral
organs, heart, colon, small intestine, lung, and liver also exhibit weak expression. Reports
about LIGHT expression in the brain are conflicting (Harrop et al., 1998; Mauri et al.,
1998). LIGHT expression in T ceils requires activation stimuli similar to those for LTŒ
and LTD. Monocytes and granulocytes may also express LIGHT (Zhai et al., 1998). But
these resuits have not been well confirmed at protein level (Harrop et al., 1998).
Mitogen-activated CD4 and CD8 T cell subpopulations from peripheral blood have
readily detectable LIGHT mRNA. LIGHT can be detected on the surface of activated T
cells (Mauri et ciL, 1998), macrophages and immature dendritic cells (Tamada et al.,
2000). Also, activated T celis do not appear to produce soluble LIGHT. However, while
LIGHT was expressed by HEK 293 cells, its observed molecular mass was 28-29 kDa
while the molecular mass of LIGHT from activated II-23 T celI une was 30 kDa. The
analysis of a truncated fomi of LIGHT (at position G85) suggests that a soluble form of
LIGHT protein retains receptor-binding activity (Harrop et al., 1998). lii contrast to LTŒ
or LTD, LIGHT is also expressed by the monocytic cell line THP-1 following activation
by phorbol ester (Zhai et al., 1998).
for the II-23 T ceIl hybridoma (CD4 T celis), both phorbol ester (PMA) and ionomycin
are required for the enhanced expression of LIGHT, while PMA is sufficient for LTŒI3
complex (Yu et al., 1999; Kuprash et al., 1996; Zhai et al., 1998). Other reagents that
activate T ceils, such as PHA or anti-CD3, or specific antigens, induce the expression of
LIGHT.
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These resuits suggested that LIGHT had a broader tissue expression pattem than LTŒ and
LTJ3 which are limited to activated T and B lymphocytes and NK celis. Although it is
wel! accepted that activated T ceil and dendntic ce!! have ce!! surface LIGHT expression,
recent findings in our laboratory suggested that LIGHT indeed can 5e detected at resting
T ceil surface without activation (Shi et al., 2002).
1.3.6.2. The receptors ofLIGHT
Three receptors from TNFR superfarni!y have been identified for LIGHT: LT R on
stromal ceils, HVEM (herpes virus entry mediator, also know as HveA) on T ceils (Mauri
et aï., 1998), and the soluble receptor TR6/DcR3 (Pitti et al., 1998;Yu et aÏ., 1999).
1.3.6.3. The biologicalfiinctions ofLIGHT
LIGHT has been intensive!y studied for its functions. Accumu!ating evidence suggests
that LIGHT p!ays critical roles in regulating immune responses by interacting witli
HVEM, LTj3R and possibly with TR6 as well.
f irst, LIGHT is demonstrated as a novel costimu!atory rno!ecu!e for T ce!! activation,
which directly resu!ts in increased T ceil pro!iferation, enhanced Thi type cytokine
production, and NF-kB trans!ocation. Moreover, the LIGHT triggered T ce!l activation
was found independent of the 37/CD28 pathway (Tamada et al., 2000A; Tamada et al.,
2000B).
In addition to induction of T celI activation, LIGHT a!so regulates antigen presenting celi
(APC) development. For instance, DCs are APCs most potent in initiating primary T ce!!
responses. It was found that blockade of LIGHT can inhibit the optimal induction of
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL XIAOCHUN WAN 30
primary T ceil responses by ailogeneic DCs, suggesting that LIGHT is a pivotai
costimulator for DC triggered stimulation of primary T ccli responses and the
costimulation is rnost likely through HVEM (TR2) (Tamada et al., 2000) on DCs. In one
report, it was found that LIGHT signaling via HVEM was in cooperation with CD4O
signaling for DC maturation. The DCs then achieves activation and thus are able to elicit
an enhanced anti-tumoral CTL response (Mord et al., 2001).
LTÇR is one of the receptor of LIGHT that piays a major role in the formation of
secondary lyrnphoid tissue during embryogenesis (Futterer, 199$). Both LTŒ1 and
LTI3W’ mice showed disappearance of lymph nodes (LN) and Peyer’s patches (PP) and a
severe disorganization of spienic structure (Fu et al., 1999; De Togni et al., 1994). To
study whether T ccii derived LIGHT and its interaction with LTf3R are sufficient to
support the fonriation of lymphoid tissues, LIGHT transgenic (LIGHT Tg) mice were
deveioped and backcrossed with either LTŒ or LTW’ mice (Wang et al., 2002). The
resuits showed that LIGHT—complemented LTŒ mice (LIGHT Tg!LTŒj dispiay
recovery of secondary lymphoid tissues and restoration of spienic architecture. In
addition, blockade of endogenous LIGHT activity in LTt3R mice give risc to more
severe disturbed spienic structure, suggesting the importance of LIGHT in the
developrnent and maintenance ofthe lyrnphoid organs and tissues (Wang et al., 2002).
LIGHT couid trigger apoptosis in some types of tumors both in vitro and in vivo. One
important supporting experiment is that LIGHT gene transfected into a human breast
carcinorna une resuited in the compiete inhibition of tumor development in T ceil
deficient athymic nude mice (Zhai, et aÏ., 1998; Harrop et aï., 199$). It was found that
gene transfection of LIGHT mediates turnor rejection through the generation of tumor
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specific CTL. This was supported by data showing that blockade of LIGHT ameliorates
acute graft-versus host disease (GVHD) by anergizing host-specific CTL (Tarnada et ctl.,
2000). However, the in vivo effects of LIGHT, particularly on T celis, can only be well
understood by using LIGHT transgenic (LIGHT Tg) and/or kiiockout (KO) animais.
1.3.6.4. LIGHT transgenic and knockout mouse models
Shaikh et aï., generated T ce!! LIGHT transgenic (Tg) mice and found that LIGHT Tg
mice displayed abnormal !yrnphoid organ structure, chaotic lymphocyte distribution in
addition to organ inflammation and destruction (Shaikh et al., 2001). T ceils from LIGHT
Tg mice exhibit an abnormally activated phenotype and elevated Thl cytokine activity
(Wang et al., 2001). Wang et aï., also found that LIGHT Tg mice exhibited an unusually
enlarged T celi compartrnent and a hyper-activated peripheral T ce!l population. In
addition, LIGHT Tg mice spontaneous!y develop severe autoimmune disease
characterized by !ymphadenopathy, glomemlonephritis, splenomega!y, enhanced !eve!s
of autoantibodies and severe lymphocytes infiltration of different peripheral tissues.
Blockade of LIGHT activity by HVEM-Ig decreases the severity of T ce!!-mediated
disease. Using the same model, it was found that LIGHT might be one of the important
costimulatory molecules functioning in the T-T celis interaction and activation required
for the complete expansion of peripheral T celis. The dysregu!ation or over-expression of
LIGHT may play an important ro!e in the pathogenesis of T celi mediated chronic
inflammation and autoimmunity. Moreover, the in vivo data showed that LIGHT is
sufficient to cause the activation and expansion of peripheral T ce!!s that subsequently
lead to the breakdown ofperipheral tolerance (Wang et al., 2001).
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These findings together suggested a profound role for endogenous LIGHT in regulating
T celi activation, presumably through costimulation to TR2 on T ceils. Moreover, these
findings aiso indicated a critical roic for LIGHT as an important T ceil costimulatory
TNF ligand in T celi activation and expansion, the dysregulation of LIGHT leading to
aitered T celi homeostasis, breakdown ofperipherai tolerance and autoimrnune diseases.
A logical question: what are the consequences of LIGHT knockout in animais? One
study from LIGHT deficient (LIGHTj mice showed that lymphoid organs are largely
intact and function norrnally as T ceiis and APCs do. But CTL (CD8) induction and
cytokines related to CTL deveiopment were reduced from LIGHT’ mice (Tamada et al.,
2002). By using LIGHT’ mice in an allograft rejection study, it was found that the mean
allograft survival tirne of LIGHT mice is only slightly prolonged whist in combination
with CsA, the survival tirne is significantly enhanced compared with normal LIGHT’
mice (Ye et aÏ., 2002). Scheu et al., found that LIGHT’ mice actuaiiy deveiop intact
lymphoid organs whereas LIGHT’ LT’ double deficient mice have low percentage of
mesenteric iymph nodes. Interestingiy, in the LIGHT, CD28’ allogeneic skin graft
rejection mice model, it was found that LIGHTCD28’ showed a skin survival of 19 d,
i.e. 6 days (d) longer than single deficient or WT mice. This suggested that LIGHT
together with CD28 plays important role in aÏÏo-graft rejection. The reason couid be the
reduced development of cytotoxic T lymphocytes as shown in the followup MLR study
on LIGHT’ mice (Schew et al., 2002).
These resuits suggested that LIGHT is necessary for activation of CD8 but flot CD4 T
lymphocytes (Tarnada et aÏ., 2002). This may be further implicated in the decrease of
allogeneic CTL activities and the delay of ailogeneic graft rejection. Together, these
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resuits suggested that LIGHT and its receptor TR2 may contribute to the organogenesis
of secondary lymphoid tissues and the important involvement of T celi costimulation in T
ceil mediated immune responses.
1.4. Interaction of TNF SfF Ïigands with their receptors
The biological function of TNFR!TNF ligand SFPs as well as their associated diseases
are dependent on an essential signaling stoichiometry. Signaling is assumed to be
achieved by ligand-induced trimerization of the monomeric receptor chains. This was
demonstrated by crystallography of the extracellular ligand binding domain bound to LT
CL (TNF f3) which showed a three to three syrnmetry of the ligand-receptor complex
(Banner et aÏ., 1993). The X-ray structure for both TNF a and TNF [3 unveiled that both
proteins exist as a “triangular colle” trimer tEck et al., 1992) and the ligand trimer binds
three receptor molecules, one at each of three TNF monomer-monomer interfaces
(Banner et al., 1993). The trimeric ligand makes contacts within the CRD 2-CRD 3
region and thus forms a hexameric complex unit containing three receptors and a ligand
trimer. Substantial data indicates that other TNF cytokine-receptor interact similarly to
this typical, obligatory 3:3 symmetry and lead to receptor activation (Idriss and Naismith,
2000).
1.5. TNfR SfF signaling
The last few years have witnessed a proliferation in the knowledge of the proteins
participating in the signaling of the TNF system. TNF receptors are activated by
interacting with their specific ligands followed by receptor trimerization or
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oligomerization and ultirnateiy iead to either apoptosis or survival of receptor-bearing
ceils according to different stimuli. The general deathlsurvivai signaling pathways can be
best iilustrated by TNT a and LT Œ which were intensiveiy studied in the past severat
years for their signaling events.
TNF a and LT a mediate their effects via two receptors: TNFR-I and TNfR-ll. These
iigands interact with both receptors as homo-trimers and induce receptor trimerization
which is pivotai for receptor activation (Nagata, 1997; Ashkenazi and Dixit, 1999).
TNFR-II has no intracellular death domain and is generaliy flot implicated in apoptotic
signais. Therefore, TNFR-I is the main receptor responsible for mediating the apoptotic
signais ofTNf receptor-ligand system (Nagata, 1997; Ashkenazi and Dixit, 1999). Upon
activation, TNFR-I recruits the intraceliuiar adaptor molecule termed “TNFR-associated
death domain protein” (TRADD). TRADD is a death domain containing adaptor
molecule which further recruits another death dornain containing protein narned FADD
(fas —associated death dornain protein) (Chiimaiyan et aï., 1995; Boidin et al., 1996). The
interactions among these adaptor molecuies and TNFR-I occur through their respective
death domains, ieaving the N-terminal death effector domain of FADD free to further
interact with the domain ofproximai pro-caspase 8 or 10. Recntitment ofproximai pro
caspase at the receptor site induces its oiigomerization-mediated activation (Ashkenazi
and Dixit, 1999). Upon activation, the proximai caspases further activate the downstream
caspases such as caspase 3, 6 and 7, also termed the executioner caspases. Once the
executioner caspases are activated, the apoptotic signai flows further downstream leading
to the cieavage of death substrates and eventually ceii demise (as shown in Figure 2).
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As presented in Figure 2, in addition to the apoptotic direction, TNFR-I also relays
signais that impinge upon celi survival. For instance, TRADD also recruits TRAF1 and
TRAF2, the adaptor molecules that lead to activation of JNK (Jun N-terminal kinase) and
NF-icB (Ashkenazi and Dixit, 1999). These TRAFs have been shown to bind to TNFR-I
and prevent TNTŒ induced activation of caspase $ at the receptor site. TRAFs also serve
to function in a positive feedback loop to further promote NF-icB activation and generate
survival signais. Recruitrnent of TRADD and FADD at the receptor site also promotes
interaction with another death domain containing molecule RIP. RTP has been shown to
interact with RAIDD to activate caspase 2 in order to mediate apoptotic signais (Wang et
al., 1999). Thus TNFR-I activation involves a complex series of interactions with
intracellular molecules to mediate apoptotic and survival signals.
Ail the other cytokine-receptor pairs of the TNF superfarnily have sirnilar signaling
events of TNF/TNFR pairs as illustrated in Figure 2 and the signaling is very rapid and
highly specific. For instance, Fas is activated by interaction with its ligand Fas-L. Just
like any other ligand in this family, FasL binds to Fas as a homotrimer and activates its
cognate receptor Fas (Nagata, 1997; Ashkenazi and Dixit, 1999). The basic paradigm of
Fas activation is similar to that ofTNFR-I except that Fas does not bind with TRADD but
directly recruit FADD.
It is worth to mention that mitochondria have an important role in apoptotic-signaling
pathway initiated by TNF receptors. The apoptotic signaling can trigger the release of
apoptotic factors from the mitochondrial intermembrane space (Gurp et aÏ., 2003). These
apoptotic factors include cytochrome C (Li et al., 2000), AIF (Wang et al., 2002),
endonuclease G (Li et aÏ., 2001; Ohsato et aÏ., 2002), Smac/DIALO (Verhagen et al.,
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2000; Du et al., 2000), Omi/HtrA2 (faccio et cd., 2000), and ACBP (Melloni et aï.,
2000). Cytochrome C induces caspase activation by binding to Apaf-1 whereas
Smac/DIABLO and Omi/HtrA can neutralize IAP’s inhibition of caspases. AW and
endonuclease G are mainly involved in caspase-independent nuclear DNA degradation
(Zamzami et al., 2001).
The release of cytochrome C leads to the formation of apoptosome which include Apaf-1
and caspase 9. Apoptosorne is closely associated to the downstream activation of
caspases 3, 6 and 7 (Creagh et al., 2003). It is believed that the cytochrome C dependent
apoptosome formation is flot an essential trigger for apoptosis but rather an amplifier of
the caspase activation cascade (Joza et al., 2001; Green, 2003).
1.6. Hypotheses
As described in the above sections, a complex picture of TR6 receptor-ligand interactions
emerged as illustrated in figure 3. TR6 recognizes three confirmed ligands: LIGHT,
FasL, and TL1 and each of these lias more than one receptor as well. The first ligand
fasL lias two receptors: Fas and TR6. Another ligand LIGHT has 3 confirmed receptors:
LTI3R, HVEM (TR2) and TR6. LTf3R can interact with its ligands: TNF u and LT u.
TL1 is the third ligand of TR6 and it has two receptors: TR6 and DR3. DR3 also binds to
TRAIL. Consequentïy, the resulting complex pattem suggests a highly sophisticated
cytokine-receptor system.
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The focus ofour study is the role ofTR6 in immune regulation. Since LTR and TL1 are
flot expressed in the immune system, our study focuses on the interaction among TR6,
LIGHT, fas, FasL and HVEM. We fonTtulated the following hypotheses.
(1). TR6 modutates inuntine responses szcch as T cet! costimuÏatioit by interrupting
several pairs of TNfSf and TNfRSf interactions
It has been confirmed that both LIGHT and FasL are involved in T ccli costimulation.
For LIGHT, the costimulation is achieved by interaction with TR2 (Tamada et aÏ., 2000);
for Fas-L, costimulation is achieved through interaction with Fas (Suzuki et a!., 2000).
Therefore, we speculate that TR6 (in soluble form) might be able to modulate T ceil
activation by interfering with these two TNF ligand-receptor pairs.
(2). TR6 011 solid phase ntight trigger reverse signa!ing through the !igand(s)
As mentioned before, some TNF ligands might have reverse signaling properties. Since
TR6 binds to FasL and LIGHT, it is possible that solid phase TR6 rnight act on these
ligands to costimulate T celis through reverse signaling.
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Article 1:
Modulation of T-ceIl responses to alloantigens by TR6/DcR3
Xiaochun Wan, Jun Zhang, Theodora W. Salcedo, Stephen U]Irich, Bugen Hu,
Theresa Gregorlo, Ping Feng, Shijie Qi, Huifang Chen, Yun Hee Cho, Yuling Li,
Paul A. Moore and Jiangping tYu
Journal of Cllnîcal Investigation, June 2001, Volume 107, Number 11, 1459-1468
Note: In this paper, as co-flrst authors, Jun Zhang and Theodora W. Salcedo contributed
in recombinant proteins and other related reagents preparation. In addition, they also
performed some important experiments as shown figure 1, 2 and 3 and Table 1 and 2.
The remaining works such as resuits shown in figure 4, 5 and 6 were performed by
Xiaochun Wan.
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TR6 (DcR3) is a new member ofthe TNF receptor (TNFR) family that lacks a transmembrane domain
in its sequence, indicating that it is a secreted molecule. TR6 can bind to FasL and prevent FasL
induced apoptosis; it can also associate with LIGHT, another TNF family member. Tise role ofTR6
in immune responses was investigated in this study. According to flow cytometry, recombinant
human TR6-fc bïnds to human LIGHT expressed on 293 cells or on activated human T ceils and
competes with the LIGHT receptor TR2 for the binding to LIGHT on these ceils. Human TR6 could
cross-react with mouse LIGHT in immunoprecipitation. TR6-Fc also downregulates cytotoxic T lym
phocyte activity in vitro and graft-versus-host responses in mice. Moreover, TR6-Fc modulates lym
phokine production by alloantigen-stimulated mouse T ceils. TR6-Fc ameliorated rejection response
to mouse heart allograft. These resuits indicate that TR6 can dampen T-cell responses to alloanti
gens. Such regularory effects ofTR6 probably occur via interference with interaction betw
een pairs
ofrelated TNF and TNFR family members, LIGHT/TR2 being one ofthe possible candida
te pairs.
J. Clin. Invest. 107:1459—1468 (2001).
Introduction
TR6 (also called DcR3) is a new member of the TNF
recepuor (TNFR) family. TR6 lacks an apparent trans
membrane domain in its sequence anti is likely a secret-
cd protein (1). The mRNA ofTR6 is expressed at high
levels in several normal human tissues such as the
stomach, spinal cord, colon, iymph node, anti spleen (1,
2), whereas its mRNA expression in the thymus is weak,
and in peripheral blood lymphocytes is undetectable.
Recombinant TR6 fused wiuh an IgGi fc domain can
inhibit tise interaction between Pas anti FasL anti pre
vent FasL-induced apoptosis in lymphocytes anti 5ev-
eral tumor cdl unes (1). Tise latter suggests that certain
tumors may escape FasL-dependent immunocytotoxic
attack by overexpressing TR6.
TR6 can also bind to LIGHT, which is a member of
tise TNF family (3). LIGHT is a type II transmembrane
protein, anti its protein is expressed on activated T celis
(4) and immature dendritic cells (5). It is a figand for
bouh TR2/HVEM and LTR (4). LIGHT was found to
induce apoptosis in celis expressing both TR2 and
LTR, but flot in ceïLs expressing only TR2 or on
ly
LT1. Ç6. However, a recent report by Rooney et aL (7
raiseti doubt about this conclusion by showing that
LTI3R is necessary and sufficient for LIGHT-mediated
apoptosis of tumor celis. In any case, as LTf3R is not
expressed on lymphocytes (8), LIGHT lias no demon
strated or perceived apoptotic effect on these cells.
Recent studies show that LIGHT can modulate T-ecu
responses via TR2, which is constitutively expressed at
both protein anti mRNA leveis in most lymphocyte
subpopulauions including CD4 anti CD8 T cells (9, 10).
Soluble LIGHT enhances a three-way MLR (11).
LIGHT expressed on COS celis or anchored on solid
phase augments T-ecu proliferation anti lymphokine
production (5, 12). Molecules that can presumably
interfere with the interaction between LIGHT anti TR2
were found to downreguÏate T-ceÏl responses. For
example, an antagonistic mAb againsu TR2 reptesses
puoliferation and lymphokine production by CD4
T cells (9); soluble recombinant TR2-Fc inhibits a
three-way MLR (9, 10) or dendritic cell—srimulaued
alloresponse of tise T cells (5); soluble LT3R-Fc inhibits
solid-phase LIGHT-augmented T-cell puolifetation
(12); anti in vivo administration ofLT3R-Fc leads to
arnelioration of mouse graft-versus-host disease (12).
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Article 2:
A TNf Family Member LIGHT Transduces Costimulatory Signais into Human T
Ceils
Xiaochun Wan, Jun Zhang, HongYu Luo, GuiXiu Shi, Kapnik E, Kim Sonhoo,
Kanakaraj P, Jiangping Wu.
Journal of Immunology 2002 Dec 15;169(12):6$13-6821
Note: In this paper, as co-first author, Jun Zhang was responsible for experiments
involving Thi and Th2 ceil surface staining and cytokine tests as shown in Figure 3 and
Figure 4. Ail the remaining works were performed Xiaochun Wan.
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A TNF Family Member LIGHT Transduces Costimulatory
Signais into Human T Ceils’
Xiaochun Wan,2* Jun Zhang,2 flongyu Luo,* Guixin Shi,* Elena Kapnik, Sunghee Kim,
Palanisamy Kanakaraj, and Jiangping Wu3*t
DcR3/TR6 is a secreted protein belonging to the TNFR timiiy. It binds to Fas ligand, LIGHT, and TLIA, ail of whicli arc TXF
famity members. LIGHT is expressed on activated T ceils. Its known reccptors are TR2 and LT3R on the ccli surface, and TR6
in solution. In the present study, we report soluble TR6-Fc or solid-pliase TR6-Fc costimulated proliferafion, iymphokine pro
duction, and cytotoxicity of human T celis in the presence of 1CR ligation. Thesc cosfimuiating cffccts were blocked by soluble
LIGHT but flot by soluble Fas-Fc. TR6-Fc could also cffcctiveiy costimulate gM/gld mouse T celis. tVe furthcr dcmonstratcd that
TR6 bound to both Thl and Th2 celis, according to flow cytornetry, and that the association was inhibited by soluble LIGHT.
Cross-iinking Thi and Th2 cclls with solid-phase TR6-Fc along sitti o suboptimal concentration of anti-CD3 enhanccd prolifcr
afion of both Thi and Th2 ceils, and augmentcd Thi but not T1i2 iymphokine production. Thcsc data suggcst that TR6 dclivcrs
costiniulation tlirough its Iigand(s) on the T ccli surface, and at least the major part of such costimuiation is via LIGHT. The
Journal of Iininuiiology, 2002, 169: 6813—6821.
M embcrs of the TNF family play important roles in diverse celiutar functions, such as proliferation. diff’crentiation, cytokine production, apoptosis, 1g class
switchinu, and T cdl costimulation (l—3). Most of them (cxccpt
Iymphotoxin u, which is entirely sccretcd) arc type Il membrane
proteins, and can excrt their cffect through ecu-ecu contact (I).
Many members, such as TNF-a (4), CD4O ligand (CD4OL)4 (4),
Pas ligand (fasL) (5), and TNF-related activation-inducecl cyto
kine (TRANCE) (6) can be clcaved from ccli surfaces. The cleavcd
parts of these members have demonstratcd (as in the case of
TNF-a) or conceivablc biological fonctions that involvc interac
tion with their respective receptors.
LIGI-IT/TL5 is a ncw member of the TNF family (7), with its
protein cxpressed on activatcd T celis (7) and immature dendritic
ceils (8). Ccli surface LIGHT can be cleaved by matrix metallo
proteinase (9). ut is a ligand for TR2/Herpesviws entry mediator,
lymphotoxin /3 reccptor (LT/3R), and DcR3/TR6, ail of which are
TNFR family members (7, 10, 11). Recent studies show that
LIGHT can costimulate T ccli responses via TR2, which is con
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stututively expresscd at both protcin and mRNA levels in most
lymphocyte subpopulations, inciuding CD4 and CD8 T cells (12,
13). LIGHT, expressed on COS cells or anchored on o solid phase,
augments T ccli prolifcration as well as iymphokine production (3,
8). Moiecules that lresumably interfere with 0w interaction be
twcen LIGHT and TR2 con down-regulatc T ccli responses: sol
uble recombinant TR2-Fc inhibits a threc-way MIR (13) or dcn
dritic ccil-stimttlatcd alioresponse of T cclls (8), an antagonistic
mAb against TR2 represscs prohferation and lymphokine produc
tion by CD4 T cells (12), soluble LT/3R-Fc suppresses solid-phase
LIGIIT-augmented T ccli proliferation (3), and in vivo adminis
tration of LT3R-Ec ieads to amclioration of mouse graft-vs-host
disease (3). Taken together, these pieces of evidence show that
LIGHT acts on TR2 as o costimulator of T ccli activation. More
ovcr, LIGI-IT can induce apoptosis in cells expressing both TR2
and LT/3R (14), althrntgh Rooncy et al. (15) rcportcd that LT/3R is
necessary and suffictent for L1GHI-mediated apoptosis in tumor
celis. Because LT/3R is not cxpressed on lymphocytes (16),
LIGI-IT is unlikcly to cause apoptosis in these cclls.
TR6 is a new member ofthc TNFR family. Human 1R6 lacks
an apparent transmcmbrane domain in its scqucnce, and is a se
creted protein (10, 17). In the immune system, TR6 mRNA is
cxprcssed at high lcveis in lymph nodes and the spleen (17, 1$),
whiie its expression in the thymus and PBIs is weak or undetect
abic, rcspcctively. TR6 has threc known ligands, i.e., fasL,
LIGHT. and TUA. TR6 con bind to FasI and inhibit thc interac
tion bctwcen fas and FasL. Consequently, fasL-induced apoptosis
of lymphocytes and ofscveral tumor ccii unes con be repressed by
TR6 (17). ‘FR6 con also bind to LIGI-iT (10, 11). We have recently
reported that human TR6-Fc con competc with TR2 for binding to
LIGHT on human T celis, supprcss CIL and Iymphokine produc
tion in mousc lymphocytes, and inhibit mouse heart allograft re
jection (10). These Ondings have t’aised the possibility that TR6
inhibits LIGHT-triggered costimulation via TR2 in T ceiis. The
third known ligand ofTR6 s TIIA, which isa ncw member ofthc
TNF farniiy, and is predominantly exprcsscd on endotheliai cclls
(19). TR6 can repress TL1A-augmented lymphokine secretion and
thc graft—vs-host rcsponsc (19).
Copyright © 2002 hy The Aincricun Association of Immuttologists. Inc. 0022- t 767/02,S(12M(J
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Our currcnt study lias rcveaied another layer of compiexity in
the interactions betwecn TR2, TR6, and LIGI-IT. We present cvi
dcnce in this study that TR6 ligand on the ccii surface actuaiiy
transduces costimulating signais into T cclis, and cnhances T ccli
responscs to mitogens and ailoantigens. At ieast a part of such
reverse signaling \vas mcdiated by LIGHT. Thus, aithough u h
gand, LIGHT can function as a receptor as weII. The biological
significance cf this finding is discusscd.
Materials and Methods
Recoo,binant Jwoteins and niA bs
Recombinant TR6-Fc, TR6, TRi l-Fc. LIGFIT. and FasL werc prcpared as
described in our previous publications (10, 20).
mAbs (clones I 7B07 and SK9E2) againsi TR6 werc prepared as fol
lows. BALB/c mice werc immunizcd i.p. with 50 g/lOt) iI ofTR6 emul
siflcd in 100 sI of CFA. Three additional se, injections of 25 p.g of TR6
in IFA wcrc given at 2-wk intervals. The animais were rested fora month
before recciving the final i.p. boosi of 25 g of TR6 in P85. Fout days
luter, spienocytes from une of the immunized mice wete fused with 2 X
io P3 X 63Ag$.653 plusmacytomu ceils using polyethylcnc glycol 1500
(Roche Applied Sciences, Indianapolis, IN) according to the manufactur
cr’s instructions. After fusion, Oie cells were resuspended in 400 ml of
hypoxanthine/arninopterin/thymidinc medium supplcmetitcd with 20%
FCS and 4% oC hybridoma supplement (Roche Applied Sciences). and
distrihutcd into 96-well plates (200 Rl/welI). Hybridomas were screened
for specific Ah production by ELISA using TR6-coated plates. Positive
hybridoma supematants were checked for 1g isotypes using amuse lso-strip
kit (Roche Applied Sciences). mAb affinity tvas ranked by ELISA accord
ing te an approach described earlier (21). 1-lybridomas producing high
affinity mAbs were cloned by limiting dilution. Cloned hybridorna cells
wcre injected in pristine-primed BALB/c mice (3 X lOt’cclls/mouse) for
ascites production. lite Abs were putified fient the ascites by protein G
allinity chromatography using Oie Acta fast protcin liquid chrornaiography
system (Amersham Pharmacia Biotech. Piscataway, N]).
Preparation cind ctdtui’e cf PBMCv, T ceils, Titi cell,ç, Th2 colis,
cind moitse spleen ceils
Aduit PBMCs were preparcd by Lymphoprep gradient (Nycomed. Olso,
Noi-ay), and T celis were prcpared front PBMC by shecp RBC rosetiing
as described eisewhere (22), or by negative selection (deletion of celis
positive for CDI lb. CDI6, CDI9. CD36. and CD56) with magnetic beads
(Miltenyt Biotec. Auburn, CA) according te the rnanufitcttirer’s instruc
tiens, lite mouse mononuclear spleen cells were prcpared by lysing RBCs
in the total spleen ceils with 0.84% NI-14C1. The cells svere ctilturcd in
RPMI 1640 supplementcd with 10% FCS, c-glutamiite, and aittibiotics.
RPMI 164f), FCS, pcnicillin-streptontycin, and c-glutaminc were pur
chascd front Lifc Technologies (Burlingion, Oniario. Canada). [‘FllThy
midine uptake svas measured as descdbed previously (22. 23).
For Titi attd 1h2 ccii generation. cord bloed mononuclear cells wcrc
isolaicd by dcnsity gradient on 1-listopaque-l077 (Signta-Aldrich. St.
Louis, MO). Monocytes from cord blood ntonenuclear cells were deleted
by culture dish adhesion for I h at 37°C, and tlte resulting lymphocyte
fraction svas cultured wittt 2 g/mi PElA (Sigma-Aldrich) in the presence
oflh l/Th2 polanzing Abs and cytokines. lit I differentiation svas triggered
by addition ef5 ng/ml IL-12 and 5 g!rnl anti-IL-4; 1h2 differentiation svas
initiatcd hy addition of 5 ng/ml IL-4, 5 jsg/ml anti-IL-12, aitd 5 g/m1
anti-IFN-y. After 72 h. celis wcre culWred in medium containing 5 ng!mi
IL-2. Afier an additional Il—14 days of culture, >99% of the ceils were
CD3” T celis according te fiow cytometiy analysis; their Titi and Th2
phenoiype svas confirmed by their lymphokine production profile, Tiiese
ceils were washed once with serunt-free RPMI ntcdiunt and starved in
lL-2-frec medium for 3 h. Tltcy were then cultured at l—2 X 10° ceils/well
in 96-wefl plates. which were coated with anti-TCRo (3 cg/ml) itt com
bination with vartous arnounts of solid-phase TR6-Fc. Proliferation of
these celis svas rneasured by [3HJthymidinc uptake 2—3 days tater. lite
ittAbs used in titis section were fiom BD PharMiitgeit (Sait Diego. CA),
and ILs were from R&D Systems (Minneapolis, MN).
Ls’mphokiite cisstiys
Flou’ cytoniet!y
liii or 1h2 ceils (I X 1 if’) witttout furtiter stimulation, or stimuluted with
sohd-phase CD3, were stained with TR6-Fc t 15 ng/sumple) followed by
goat Fiai,’), anti-iturnan IgG-PE f Souihern Bioiechnoiogy Associates. Bir
rninghant, AL). in sente sampies, TR6 without the Fc tag. LIGHT, or
anti-1R6 mAb svus preseitt as an inhibitor (5 j±gisampie) during the stain
ing process. lite ceils wcre wushed and resuspended in buffer contaitting
0.5 .cg/ml propidium iodide; propidiunt iodide-negutive live celis were
gated and anuiyzed by flow cyiometry.
Cvtotoxic T oeil cissag
CIL activiiy of ytSl ceils ts’as assayed as foiiows, Hurnan PBMC (4 X iOt
eells/200 piiwell) wcrc stimuiated with mitomycin C-ireated Daudi celis
(0.7 X 10° cells!well) in round-bottont 96-well plates in Oie presence oC iO
Uimi IL-2 for 6 days. Normai Ituman igG (20 ig/ml), 1R6-Fc (20 ig/ml),
or LIGFII (10 ig/ittl) was added te the culture in tite bcginiting. On day 6,
ceils given the sante treatment in lite 96-weli plate were pooled attd
ceuitted, aitd titeir CIL activity was ntcasured by u standard 4-h °‘Cr
release assay using °‘Cr-labeled Daudi cells (1.5 X I if celis/wcli) as tar
gets al diffcrent E:T ratios, le test ihe effcct cf soiid-phase TR6-Fc, lite
‘otind-bettom wells were precoated with 1R6-Ec (0.5 j.tg/50 p]!wefi) ut
4°C evemiglit and washed with PBS. PBMC (4 X iO cclls/250 sLweli)
and miternycin C-treatcd stimuiator Daudi cells (0.7 X 10° cells/sseli) svere
cuitured in these wells svith IL-2 (10 UIntl) in the absence or preseitce cf
soluble LIGHT (20 cgImi). On day 3, 7f) ii culture supcrnatant/well svas
replaeed with fresit reguiar ntedium. Ail the other procedures et lite CTL
assay wcre the sanie as described above. excepi that the °tCr-relcasc assay
was cenducied on day 5 instead cf day 6.
lite lysis pci’ceittagc cf the test santples ovas calcuiated as foliows:
cpm efthe test sample
— cpm of spentaneous release
/o lysis =
cprn cf ntaximal release
— epm et spontaneeus release
For a T ccli CIL activity, PBMCs front doner A svere used as responder
cetis, und ntitomycin C-treated PBMCs front donor B were used as stim
ulaters. PBMCs front dottor B without milomycin C treatment were aIim
ulaied with solid-phase unti-CD3 and anti-CD28, aitd used as target celis
en day 6 for the 4-h °‘Cr-release ussay. Ail tite other procedures were the
sanie as describcd above.
Resuits
TR6—Fc enhonced pi’ollfitratio,i c.if’ PB4tC stinutiateci bv
suboptinial concentra rions f lnitogc’ns
We made ait intriguing discoverv in the ccttrse cf our study on the
role ofTR6 in immune regulation: soluble TR6-Fc augrncnted re
spense of human PBMC stirnulated with different concentrations
ofPKA (0.05, 0.1, 0.5, and t p.g/ml) in tite presence ofTR6-Fe (20
.cg/mi) (Fig. lA). TR6-Fc grcatly enhattced the PBMC prolifera
tien when PHA vas ut suboptirnal concentrations (0.1 and 0.5
(.Lg/ml). Using a suboptimal concentration of PI-lA (0.2 .rg/ntl), we
fui’thcr demonstrated that soluble TR6-Fc ceuld enhancc PBMC
proliferation in a dose-dependent tiiantier from 0.3—30 j.cg/ml (Fig.
18). Te ensure that the cffect cf TR6-Fc plus PI-lA was net due te
u shift itt proliferation kittetics comparcd tvith that cf PI-lA or
TR6-Fc stitrntiation aJonc. PBMC stimulated with PHA (0.2 sg/
mi), TR6-Fc (10 j.cg/mi). or both tvere harvested at 48, 72, and
96 h. The result (Fig. 1C) showed tltat at no tirne points did
TR6-Fc or suboptimai PHA alone lead te sigttificant proliferatien,
unlike PHA plus TR6-Fc, ruling eut a possible kinetic sltift. Sol
uble TR6-Fc (10 sg/mi) also augrnented suboptimal soluble anti
CD3 (100 ttg/mI)-stintulated proliferatioti, as shewn in Fig. ID.
The results of this section demonstrate that TR6-Fc can stirnulate
PBMC and T ceils, likely via its ccli sctrface hgand(s).
TR6 can intcract with two ligands on the T ccli surface, LIGHT
and FasL (11, 17). The third TR6 ligand, TLIA, bas littlc expres
sioti in T eeils (19), and thus is net relevant in our systetil. To
identii’ whether LIGHT or FasL was respensibie fer receiving
TR6 stimulation, we added soluble LIGI-IT (10 j.cg/ml) or Fas-Fc
(10 j.tg/mi) te T cells stimulatcd with a sctboptimal conceittratioti
cf PI-lA (0.2 Lg/ml) itt combinatien with sehd-phase TR6-fc (Fig.
IL-2. IL-5. IL-6, IL-10. IFN-y, INF-a, and GM-CSF in culture superna
tants wcre nteasured by commercial ELISA kits fient R&D Systems.
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FIGURE I. TR6-Fc strongly promoted proliferation oC PHA- or anti-CD3-stimulated PBMC and T relis. Hurnan PBMC or T relis, or mouse spleen relis,
wcre stimulated with suboptimal concentrations of Pi-lA or anti-CD3. Soluble or selid-phase TR6-Fc vas used for costimulation. Ccli proliferation was
measured by [3HJthymidine uptake at the tintes indicated. Mean ± SD ofthe cprn from triplicate samples are shown. The experiments wcre performed more
than three urnes. and a representative set of datais presented. .4, Elfcct ofTR6-fc on PBMC stimulated with various doses ofPHA. PHA was used att),05,0.1, 0.5, and I jLg/ml. and TR6-Fc in solution svas used al 10 .rg/ml. [3HJThymidine uptake by the cclls between 48 and 64 h after initiation ofculture
was mcasured. B. Effect of various doses of TR6-Fc on PBMC stimulated with a suboptirnal dose of PHA. TRG-Fc in solution svas used at 0.3, I. 3, 10,
and 30 tLg/rnl, ‘hile PHA was used at a suboptirnal dose of 0.2 ig/ml. [3H]Thymidinc uptake by the relis vas measured at 48 and 72 h. C, Proliferationkinetics ofPBMC stimulated by TR6-Fc and e suboptirnal dose oC PHA. PBMC were stirnulated with 10 rg/ml TR6-Fc in solution along with 0.2 ug/mlPI-lA. The proliferation of these cells ‘as measured ut 4$, 72, and 96 h. D, Effect of TR6-Fc on PBMC stirnulaled with a suboptimal concentration of
anti-CD3. PBMC were stimulated with TR6-Fc (10 jLg!ml) in solution and a suhoptimal concentration of soluble anti-CD3 (50 ng/rnl). Cr11 proliferation
vas measured at 48, 72, and 96 h. E, Soluble LIGHT inhibited solid-phase TRO-promoted proliferation of PHÀ-stirnulated T cells. t-Iuman T ceils were
cultured in the presence ofa suboptimal PI-tA concentration (0.2 .og/rnI). solid-phase TR6. or both as shown. To prepare solid-phase TR6. the wells wereprecoatcd overnight at 4°C with nonneutralizing anti-TR6 rnAb (clone I 7B07, 251) ng/5l) pi) in PBS, followed by TR6-Fc (I ig/50 fil) at room temperaturefor 6 h. Soluble LIGHT vas added as indicated to certain samples at 10 jig/ml. [3HJlhvmidine uptake between 4$ and 64 h after initiation of culture svas
measured. F, Effect of solid-phase TR6 on anti-CD3 stimtilated gtcl/gld noouse spleen cells. Solid-phase TR6-Fc and anti-CD3 were prepared by coatingNUNC wells with 5 ig/ml goat anti-human lgG (Southem Biotcchnology Associates) along with various concentrations (0.1—0.5 ig/ml) of anti-CD3 inPBS as indicated ovcrnight et 4°C. After washing, the wells were incubated with TR6-Fc (10 ffg/rnl) or buffer (P35) at 37°C for 2 h. The coated wellswere thon used for culture. Spleen ceils ofC57BL/6 or gld/gld mice in 36 background were cultured in the coated wells and [311]thyntidine uptake between48 and 64 h after initiation of culture vas measured. C57-TR6-Fc or GLD-TR6-fc: C57BL!6 or gld/ghl spleen cells. respectively. cultured in wells coated
with anti-CD3 and TR6-Fc; (‘57-buffer or GLD-huffer: C57BL’6 or gtci/g/d spleen cells. respectively. cultured in wells coated with anti-CD3 alone followedby incubatton of buffer during the second coating period. G. Offert ofTR2 on anti-CD3-stimulated BALB/c mouse spleen relIs. Solid-phase TR2-Fc and
anti-CD3 tvas prepared as descrihed in F, except 10 j.rg/ml TR2-Fc svas used in the place ofTR6-Fc. Buffer: wells coated with anti-CD3 in the first coating
and buffer in the second coating; TR2-Fc: wells coated with anti-CD3 in the first coating and TR2-Fc in the second coating. [3H)Thyrnidine uptake between48 and 64 h after initiation of culture vas rneasured. H. Comparison of solid-phase TR6-Fc vs TR6 without Ec for their stimulation efficacy of T cellproliferation. TR6-fc, TR6, or a conirol fusion protein TRI I-Fc svas directly coated on wells (1 ug.’50 pi/well during coating). PBMC werc caltured in
these wells in Ihe absence or presence of a suboptintal concentration of PI-lA (0.2 .ug/tnl). [3H]thymidine uptake between 56 and 72 h after initiation of
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lE). The solid-phase TR6-Fc in this experiment vas preparcd by
coating the culture wells with nonneutralizing anti-TR6 rnAb
(clone l7B07) followed by TR6-Fc. [3H]Thymidine uptake tvas
measured 72 h later. Solid-phase TR6 enhanccd T ccli prolifcration
in the presence ofsuboptimal PI-lA concentration, indicating that it
delivers a costimulation signai through its binding partners on T
celis. TR6 has two known hands on T ccli surface, LIGHT and
FasL. ldeally. to identii’ which ligand tvas involved in the process,
soluble LIGHT and FasL shouid be used as blockers in the culture.
The former vas used for this purpose. 1-lowever, because exoge
nous FasL in solution might lead to apoptosis of activated T cells,
it could flot be used as a blocker for this purpose. Thus. we used
soluble fas-Fc, which would bind to FasL and block the interac
tion between Fasl. and TR6. The result showed that LIGHT but not
Fas-Fc inhibited the proliferation, suggesting that LIGHT is a
likely molecule through which TR6 induces activation of T ceils.
One could argue that soluble LIGHT might block the binding of
TRÔ to fasL, and soluble fas might have lower affinity than TR6
in FasL binding (although thcre is no evidence for this assumption)
and thus eannot effectively compete with TR6 for binding to FasL.
With such assumptions, whether it is the LIGHT that transduccd
siznals into the celis remains in doubt. To gain additional evidence
for LIGI-IT-mediated reverse signaling, solid-phase TR6 vas used
to stimulate gldigld mouse spleen ceils, which have nonfunctional
FasL. J-luman TR6 can effcctiveiy bind to mouse FasL (data not
shown) and LIGHT (10). gk//g/d spleen ceils responded well to
solid-phasc TR6 stimulation (Fig. IF). suggesting that the major
part of thc reverse signaling is not via FasL. Solid-phasc TR2,
whieh binds to LIGHT but not FasL, costimulatcd mousc T cdl
proliferation when they were triggcred by suboptimal solid-phasc
anti-CD3 (Fig. 1G). Taken together, these data ffirther indicate that
LIGI-IT is the main molecule mediating the TR6-triggercd reverse
signaltng.
To compare the cfficacy of dimeric TR6-Fc vs monomcric TR6
without Fc on T ccii stimulation, and to test the hypothesis whether
thc observed stimulatoiy effcct ofTR6-Fc vas due to bloeking of
a putative ncgative rcgulatory autocrine loop by TR6-Fe or TR6
ieakcd into solution (sec Discussion for futiher elaboration), wc
coated these moleculcs directly on wells (I ig/50 sl/weii during
coating). PBMCs wcre ctdtured in thcse wells in the preswc of a
suboptimal concentration of PHA (0.2 sg/ml) for 72 h, and thy
midine uptake tvas measurcd. As shown in Fig. 1H, TR6-Fc but
not TR6 could enhance T cdl prolifcration. This showed that thc
power of cross-linking is correlated to the efficacy of TR6 stimu
lation. Morcover, this indicates that the existence of a negative
regulatoiy loop is unlikely, because if so, monomeric TR6 without
Fc Ieakcd into solution should more effectively enhance T cdl
proliferation than dimeric TR6-Fc.
TR6—Fc costiniuiation lad to augmentation oJ lymphokine
production by PBMC
1-luman PBMCs were cultured in the presence of a suboptimal
concentration ofPHA (0.2 ig/ml), PI-lA plus TR6-Fc (20 sg/ml).
or PHA plus eontrol recombinant protein TRII-Fc (20 sg/ml).
The cytokines secretcd into the supernatants at 24, 48, ancl 72 h
were tested with ELISA and the results are presented in Fig. 2A.
Because NIA tvas used at a suboptimal concentration, it induced
minimal cytokine production. When TR6-Fc vas added to the cul
ture, il drastically indueed production of cytokines such as IL-2,
IL-6, IL-10, GM-CSF, IFN-y, and TNF-a. In contrast, control pro
tein TRI I -Fc in combination with PI-lA did flot augment eytokine
production. Some Th2-type cytokincs, such as IL-4 and IL-5, werc
of veiy low levels in this system, and no changes wcre dctccted
(data not shown). Thus, costimulation from TR6-Fc lcd to aug
mentcd cytokine production in PBMC.
To assess whether the effect of TR6 tvas directiy on T cells,
TR6-enhanced lymphokine production tvas testcd in purified T
cells, which tvere stimulated with a suboptimal concentration of
solid-phase anti-CD3 aiong with solid-phase TR6-Fc anchored in
dircctly t’ia anti-human igG. Solid-phase TR6 significantly en
haneed thc TNF-cs and IFN-y production at 48 h by T celis (Fig.
1B, top tuo panels), as with total PBMC. Soluble LIGHT, but not
a control protein, TRI I-fc, prevented the augmentation of lym
phokine production. This suggests that costimulation of TR6 is
delivered to the T celis through a ccli surface TR6 ligand, with
LIGHT being a likely candidate. When stimulated with a subop
timal concentration of PHA in solution and solid-phase TR6, these
T celis aiso augmented IL-2 and GM-CSF production, compared
with PHA stimulation alone (Fig. 2B, bottom two pcmels).
TR6 bound to LIGHT expressed on Thi and Th2 ceils
LIGHT expression is up-reguiated on aetivated T cells (7): we
showed previously that TR6 spccifically bound to LIGHT cx
pressed on those ceils (10). In this study, we examined LIGHT
expression and association of TR6 with LIGHT on Th I and Th2
cells. These cells were stimulated with solid-phase anti-CD3 over
night. As shown in Fig. 3, ,ow J, TR6-Fc bound to anti-CD3-
aetivated Thi and Th2 cells (shaded areas), but not to oncs tvithout
activation (sohd lines). Unlabeied soluble TR6 (Fig. 3, row 2 with
out thc Fc tag) and anti-TR6-mAb (Fig. 3. bottant ,ma) inhibitcd
the TR6 staining, indicating that the binding was not nonspecific.
Soluble LIGI-IT (Fig. 3, cou’ 3) cffcctively bloeked the staining of
TR6-f e. These rcsults stiggest that the ligand of TR6 (likeiy
LIGI-lT) is expressed on aetivatcd ThI and Th2 celis.
TR6 costbnulotion On Thi and Th2 cdl protijèration and
iviuphokine production
Wc next assessed whether TR6 ditfl.rentially promoted Thl or Th2
function. In the presence of suboptimal solid-phase anti-TCRaf3.
solid-phase TR6 stimulated proliferation of both Thi and Th2 ecils
similariy and dose-dependently (Fig. 4, A and B); TR6-fe aione
without anti-TCR signaling had no effect on these cells (data not
shown). As these Thl and Th2 celis were >99% put-e T celis, this
expedment excluded the possibility that the effect of TR6 was
indirect via dendritic celîs or monocytes/macrophagcs. TR6 ncu
tralizing mAb (clone SK9E2) suppressed TR6-enhanced Thi and
Th2 proliferation in a dose-dcpcndent manner, while control
mouse lgG had no effeet (Fig. 4, C and D), indicating that the effect
ofTR6 is speciOc.
As TR6 showed no differential effect on proliferation ofThl and
1h2, we next examined its effect on iymphokine production by
these cells 48 h after restimulation (Fig. 4, E and F). As controls,
anti-CD28 and suboptimai anti-TCRci on the solid phase resulted
in dramatic IFN-y production by Thl but not Th2 celis (74,936 ±
56 vs 72 ± 23 pg/ml), and marked IL-5 production by Th2 but not
ThI ceils (586.9 ± 16.5 vs 1.1 ± 0.14 pg/mI), confirniing the Thl
and Th2 phenotype of the cells. When sohd-ph:tse TR6-fc vas
used aiong with anti-TCRc43, it sigmficantly increased IfN-y pro
duction by Thl ceils (42,587 ± 4,535.2 pg/ml), eompared with
anti-TCRa stimulation alune (8,064.5 ± 223 pg/ml); this aug
mentation vas biocked by anti-TR6 mAb in a dose-dcpendcnt
manner, showing the speeiflcity of the 1R6 stimulation (Fig. 4E).
IL-5 production by the ThI cells was negligible (<5—10 pg/ml)
with such stimulation, as expccted, sinee IL-5 is a Th2 iympho
kine. Th2 cells stimulated with TR6-Fc and anti-TCRcr produced
httle IFN-y (<30 pg/ml), as expccted, since IFN-y is a ThI lym
phokine; however, they also faiied to produce Th2 lymphokinc
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FIGURE 2. TR6-Fc strongly augmented cytokine production by PlIA
stimulated PBMC and anti-CD3-stimulated T celk .4, Human PBMC wore
culturcd in the presence ofa suboptimal concentration of PHA (0.2 jig/ml).
PHA plus soluble TR6-Fc (20 ig/ml). or PHA plus control recombinant
protein TRÏÏ-Fc (20 ig!mI). TOc cytokines secreted into tOc supernatants
al 24.48, and 72 h were tested with ELISA. Samples wcre in duplicate. and
tOc menus SD of lyrnphokine levels are shown. TOc cxperiments were
conductcd at lcast twice with similar rcsults. A representative set of data is
prescnted. B, Peripheral blond T ceils were cultured in wclls coated with
TR6-Fc and a suboptimal concentration of anti-CD3 (top puneI.s. In some
culture, tOc T ceils were cultured in the presence of a suboptirnal concen
tration ut PHA (0.2 pgiml) in wells coated with TR6-Fc (bottoin panels).
To prepare soiid-phase anti-CD3, the wells of 96-weil plates were cnated
overnight at 4°C with 2.5 ng/50 l/weil anti-CD3 (OKT3) in PBS. To
ThJ Th2
BIockcdith 1’J’\.__.j 1Ï/\,,,,,,j
6 1 fl5
flIGHT
: • ,,
I
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FIGURE 3. LIGI-IT was tOc major TR6-Fc ligand on activatcd TOI and
Th2 cells. Human Thi and Th2 ceils were polarized for 13 days, and
reactivated with solid-phase anti-CD3 (clone UCHTI, I jsg/ml for cnating)
ovcroight. Binding of TR6-Fc (15 ng!samplc) with thcse cells (I X I0’
cells/sarnplc) vas detected by mw cytornetry using PE-conjugated goat
anti-human IgG. Soluble TR6 without tOc Fe tag and LIGHT was used as
inhibitors (5 j.tg/sarnple) during tOc staining, as indicated. Soiid lines: relis
without anti-CD3 reactivation; shaded arca: cells reactivated with solid
phase anti-CD3 nvemight.
IL-5 (Fig. 4F). Thc resuits ofthis section show that TR6 cnstimu
iatinn preferentially augments Thi but not Th2 ccii function in
ternis of production of certain Iymphokines, althnugh it stimulated
sirnilar proliferalion responses of both ccli types.
TR6 cind LIGHT on CTL developntent
b ftirther asscss thc functional consequence nf TR6 cnstimula
tion, we cxamined thc CTL dcvclopment of PBMC in the presence
of soluble TR6-Fc. As TR6 expresses in many gastrointestinai tu-
mors (Ref. 17 and our unpuNishcd observations), and —10% of
hurnan intestitial intraepithclial T cells are y3 T cells, wc decided
to examine the ctfcct ofTR6 on CTL activity of y6 T cells. For this
puipose, Daudi cells, which arc known to elicit massive expansion
ofVy9V62 T cefls and are recognized in a TCR-depcndent fashion
by these T cells (24—26), tvcre uscd as both stimutators and targets.
As shown in f ig. SA, y5 CTL activity was enhanced by soluble
TR6-Fc but not normal IgG, in agreement with tOc proliferation
and cytokine stttdies shown in figs. 1 and 2. Wc further dcmon
stratcd that soluble LIGI-1T signiflcantly inhibited unmanipulated
(wtlhout involvemcnt of TR6) CTL activity (Fig. 58), sugges6ng
tOc tmpnrtance of LIGHT reverse signaling in u y8 CTL response.
prepare solid.phase TR6. tOc wciis wcre flrst coatcd overnight at 4°C with
anti-human IgG (250 ng/50 iil/well) in PBS, fnilowcd by TR6-Fc (250
ngiSO jil/weil) in PBS at room temperature for 6 h. Soluble LIGHT or
controi recombinant protein TRi l-Fc (10 g/mi for both) svas added In
some cultures, as indicated. The culture supcrnatants were harvesird ut
48 h and assayed for TNF-a and IFN-y (top panels), or harvested ut 24, 48,
and 72 h for IL-2 and GM-CSf (hnttom panels). Sampies were in dupli
cate. The experirnents were perfomted more than twice, and means ± SD
of n reprcseutative experirnent are shown.
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FIGURE 4. Etïects of TR6 costimulation on pto
liferation and lymphokinc production ofThl ami Th2
ceils. Th I and Th2 celis werc cuitured in the presence
of subopiimal solid-phase anti-TCRap and var,ous
arnounts of solid-phase TR6. To prepare solid-phase
anii-TCRa and TR6, the wells of 96-weli plates
were first coated overnight at 4°C with 50 rl/well
PBS containing 250 ng goal anti-human lgG and 250
ng goat anti-mouse lgG. After washing. the wells
were incubated with 50 pi PBS containing 3 pg/rnl
anti-TCRcs ami various concentrations of TR6-Fc,
as indicated. In some wells. humun lgG svas used in
place of TR6-Ec as a control. i and B, Solid-phase
TR6 enhanced Thi ami Th2 proliferation dose-depen
dently. Ccli prolifettion vas measured by [3HJthy-
midine uptake 2 days after initiation of culture.
Means ± SD of triplicate are shown. Similar resuits
were ohtained in three experimenis. C and D. Anti
TR6 mAb neutralized the enhancing effect of solid
phase TR6 on Thl and Th2 proliferation. ThI and
Th2 ceils were stimulated with a suboptimal concen
tration of solid-phase anti-TCRa and an optimal
concentration of solid-phasc TR6-Fc (20 j.tg/ml dur
ing coating). Anti-TR6 mAb (clone EO,) of various
concentrations, as indicatcd. was added W the culture;
normal mouse lgG I was used as a control. [31-ljThv—
midine uptake 2 days after initiation of culture was
rneasured in tdplicate, and means ± SD are shown.
Similar results were obtaincd in ihree experintents.
The two bottom curves with hollow symbols in each
panel were sampies stirnulaied with anti-TCRa in
the absence ofsolid-phase TR6. E and F, Differential
effccts oC solid-phase TR6 on ThI and Th2 cylokine
production. Supernatants from samples of C and D
were collected 4$ h after initiation oU culture, and
their IFN-y (E) and IL-5 (F) levels were determined
by ELISA.
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Morcovcr, solid-phase TR6-Fc similarly cnhanced y5 CTL activ
ity, like soluble 1R6-Fc, and such enhancement could be neutral
ized by soluble LIGHT (f ig. 5C), suggesting that LIGHT is the
likcly moleculc that TR6 interacts with, and that cross-linking
LIGHT costirnulatcs T cclls in yl CIL dcvelopment. We also
demonstrated that solid-phasc TR.6 could augment a I cdl CIL,
using T ccli blasts as target colIs (Fig. 5D). Tise revclation ofsuch
effcct of TR6 under physiological conditions is discusscd Inter.
Discussion
In this study, we report that soluble TR6-f e enhanced T cdl pro
liferation, cytokine production, and CIL dcvelopment, which
could be blocked by soluble LIGHT. Moreover, TR6-Fc-enhanced
proliferation could also bc observed in gÏd/g/d T cells. Such co
stimulation preferentially promoted TitI but not Th2 cclls in their
lymphokinc production. Binding studies showcd that the associa
tion betwcen TR6 and both ThI and Th2 cells cottld be inhibited
by LIGHT. Taken together, these results indicate that the ligand of
TR6 on T cells actually receives costimulating signais, anti LIGI-lT
ts likely tnvolved in thc process.
Wc werc initially perplexed by tise finding thnt soluble TR6-Fc
enhanced proliferation and cytokine production in suboptimally
mitogen-stimuiated PBMC. Is this bccause TR6 cross-rcacts with
other mcmbcrs of the TNF family and thus blocks their putative
negative effcct on T cells via their receptors? So far, no TNFR
members, including Fas and TR2. arc known to transducc negative
signaIs into T cclls to inhibit their activation. Thcreforc, no mattcr
lsow weII TR6-Fc cross-reacts with other TNf members, no pos
itive signais will be gcnerated. Thus, we are left with n more plau
sible mechanisns: TR6-Fc cross-Imks its ligand on the T ccli sur
face. and tise ligand revcrsely transduces costirnulating signaIs into
T cells. In this model, soluble TR6, although a TNf R nsember
functions as n ligand, while its ligand functions as a receptor. How
plausible is this reverse signahng hypothesis? We established a
more clear-cut system by putting TR6 on the solid phase to sec
whether it could trigger T ccli activation. In this system, tise pos—
sibility that TR6 functioned as n blockcr to repress tise putative
inhibitory interactions bctwcen any TNF nsembers and TNFR
members vas exciuded, as TR6 was flot in solution, and its total
amount vas minute. In tise presence of TCR cross-linking (e.g.,
PHA in Fig. lE, anti-CD3 in Fig. 28, anti-TCRm in Fig. 4. or
alloantigens in f ig. 5, C and D), solid-plsase TR6-fc augmetsted T
ccli proliferation, lymphokine production, and CIL developnsent,
confirming that TR6 can reversely and directly costimulate T ceils.
Soluble LIGI-IT inhibitcd TR6-enhanced proliferation (fig. lE)
and lymphokine production (Fig. 28), and repressed CIL devel
opment (Fig. 5, C atsd D). Morcover, LIGHT inhibited the binding
between TR6 and activatcd Thi or Th2 colis (fig. 3). It is ac
knowledged that the use of soluble LIGHT as a blocker cannot
prove convincingly tisat LIGHT mediates tise reverse signaling,
because one eouid reasonably argue tlsat soluble LIGhT bas
blocked the binding site ofTR6 to fasL, wlsich is also capable of
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FIGURE 5. ÉWect of LIGHT reverse signaling on CTL developmenLA, Soluble 1R6-Fc enhanced y8 CIL developmenL Human PBMCs were
stitssulated with mitornycin C-treated Daudi cells fa B cdl lyrnphorna ccii me) for 6 days. 1R6-Fc (20 ig/ml) or normal hurnan lgG (NH lgG. as a control,20 ig!nsl) was added 10 the culture in thebeginning. CIL activily in tIse stirnulated clls svas measured on day 6 by a standard 4-h 5tCrrelease assay, using
Daudi cells as targets on day 6. Percentage of targct cdl lysis s shown. Ihe experiments were perfomsed twice with similar results, and the data of a
representative cxpchment arc prescnted. B, Soluble LIGHT inhibiled y6 CIL development. Ihe experiment svas performed as describcd above, but in the
absence of soluble TR6-Fc. Soluble LIGI-IT (10 j.cg/ml) vas added in the beginning of tise culture. C, Solid-phase TR6-enhanced y6 CIL activity and
soluble LIGHT neutralized such enhancement. Ihe expehment svas perfornied as described in A, with following modifications, lite round-bottont wells
wcre precoated with IR6-Fc ((1.5 tg!50 jiLwcll) ovcnsight at 4°C and then washed wilh PBS. CeNs secte cultured in these wells containing 250 .rl medium
tu the absence or presence of 20 g/rnl soluble LIGFII. On day 3 ofthe culture, 70 IiI ofsupernatants per well wcre replaced with fresh complete medium.
Tise 51Cr-teiease assay svas cotsducted on day 6. D, Solid-phase TR6 enhanccd cs CIL activity. Ihc experiment was perforrned as described in A. except
that mitomycin C-treated PBMC from a second individual svas used as stirnulators. These ?BMCs without mitomycin C-treatrnent were stimulated with
solid-phase anti-CD3 attd anti-CD2$ for 6 days. and svere thcn used as target cells in tise standard 4-h 51Cr-t’eiease assay.
reverse signaling (27—29). To addrcss this concerts, we uscd solid
phase TR6 to costiniulate gld/gld mouse T celis, which have mu
tatcd nonfstnctional FasL, in thc presence ofsolid-phase anti-CD3.
At 0.5 jig/ml of anti-CD3, wild-type and gld/g/tI spleen ceNs sim
tlarly augmented proliferation in the presence of TR6; although at
lower anti-CD3 concentrations, gld/gld splcets ceils respotsdcd
somewhat less well. We are flot sure whether such a difference is
due tu tise involvement of FasL, but it is obviotts that 1R6 eould
significantly costimulate T celis in the absence offunctional FasL.
Moreover, TR2, which binds LIGHT but flot FasL, could aiso eu
stimulate mouse T celis in the presence of suboptimal anti-CD3.
Our must recent study revealed that tise major ccli sttrface ligand
that TR6 bitsds was LIGHT, because TR6 bound weli to wiid-type
T ceils but bat most of such binding in LIGHT gene knockout T
cclls (data flot shown). Taken together, these data suggest that a
TR6 ligand on tise T ceH surface eau revcrsely receive costimula
tion signais from its receptors, and that at Ieast a niajor portion of
such costimuiation is via LIGI-IT. With that said, wc catsnot mie
out tise possibility that a small fractton of tise reverse costtmulation
might also be mediated by fasL, or other so far uncharactcrizcd
TR6 ligand(s) on the T ccli surface. As TLIA, the most recently
discovered ligand ofTR6, ts flot expressed on lymphocytes (19), it
ts thtts unltkely tu be involved in such reverse signaliflg.
Reverse signalitsg through ligands is flot a far-fetched concept.
Several TNF members on ccii sctrfaces can revcrseiy transdttce
signais into ceils as with LIGHT. Lanier and colleagues (30) and
Gray and colieagues (31) showed that CD4OL transdtices costimu
lation signais into T ceils. Wiley et al. (32) reported that CD3O
ligand cross-iinking activates neutrophils, and Cerutti et al. (33)
showed that such reverse signaling inhibits 1g class switch in B
celis. Reverse signaling through nsensbt’ane TNf-u confcrs resis
tance of monocytes and flsacrophagcs tu LPS (34). Cross-iinking of
TRANCE enhances IFN-y secretion by activated Tisi cells (35).
Reverse signaltng through FasL can promote maximal prolifera
tiots ofCD8 cytotoxic T celis (27—29). Cross-linking ofTRAIL by
its solid-phasc death reccptor 4 incrcases IFN-y production and T
ccli proiifcratiofl (36). in the case ofCD4OL, its ligation results in
general protein tyrosine phosphot’viatiots, Ca2 itsflux, and activa
tion of Lck, protcin kinase C, c-Jun N-terminai kinase, and p38
mitogen-activated proteifl kinase in EL4 thyoma celis (37, 38).
TRAIL cross-hnking also induces p38 mitogen-activated protein
kinase activation (36). Thereforc, it shouid flot be surpdsing tisat
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LIGE-II can aiso rcccive signais from its rcccptors. Tbe rnechanisrn
of signal transduction via LIGI-IT is unknown at this time. LIGHT
bas a short and featureless cytoplasmic tau (7). Thereforc, the sig
naling viH must Iikeiy depend on molecules it associates with.
Wc recently reported that human TRÔ-Fc could bmd to mouse
LIGHT, and that httman TR6-Fc inbibited CIL in vitro and allo
graft rejcction in vivo in mice (10). In that paper, the proposed
mecbanisms ofthosc observations were that TR6 blockcd the co
stimulation from TR6 to TR2, or reversely from TR2 to LIGHT
(10), or both, although at that time, solid evidence of reverse sig
naling through LIGHT tvas nul available. Our cuiTent findings
have fulfihied une ofour initial predictions that the inhibitory effect
ofhuman TR6 in the mouse system shouid be attributed tu TR6’s
interference with the bidirectional costimulation between TR2 and
LIGI-IT. However, huw can we explain the seemingly opposite
effects of soluble buman TR6-Fc on human and mouse T ccli re
sponses? The Ec portion used in TR6-Fc and TRI l-fc was mu
tated to eliminate FcyR binding, and TR6-fc ducs not bind to
eithcr human or mouse Fc7R-bearing eefls (data not shown).
Thercfore, tbe opposite effects of TR6-Fc cannot be explained by
ils effective anchoring, or the lack of it, un feyR in the human vs
mouse systems, respectively. Rather, this might be a resuit of dif
ferent affinity of human TR6 for human and mouse LIGI-IT. De-
cause TR6-Fc is a dimer (data not sbown), in theoiy it can play
dual roles whcn addcd itou solution: as an inhibitor blocking the
bidirectional interaction bctwcen TR2 and LIGHT, or as a co
stimulator cross-linking LIGI-IT. The former inhibits T ccli re
sponse while tlw latter enhances it. Its final cffect should be the
sum of these two opposite functions, which migbt have different
affinity reqttirements. In the hurnan system, we behcve that higher
affinity betwcen TR6 and LIGI-IT tips the balance toward costirnu
lation; in the mouse system, putative lowcr affinity bctwccn human
TR6 and mouse LIGHT does net result in sufficient LIGHT cross
linking, but might be enough for TR6 tu interferc with the binding
between TR2 and LIGHT. further studies are nceded tu examine
this hypotbesis.
When a stimulatory effect of a moiecule is feund, wc aiways
bave to distingtHsh betwcen two pussibilities: the said molecule
indecd bas a positive effect. or inhibits an existing negative rcgu
iatory ioop. Dues 1R6 block an existing negative autocrine loup in
which LIGHT acts as a receptor? This possibility is best argued
against by the fact that in our model, solid-phase TR6-Fc cuuld
stimulate T ceils. Whcn TR6-Fc vas used tu coat the plate, ai
though a concentration of l—2 j.rg/iOO l/tveil vas used, only a
very small fraction of it actualiy tvent ente the plate, and >99.9%
of the protein vas washcd away after the ceating prucess. Tbus,
not >2 ng ofTR6-Fc was actuaiiy coated on a weli. If we consider
hotv small a fraction of Ibis will leak into solution, it is uniikeiy
sucb e minute amount of soluble TR6-Fc couid interfere with an
autocrinc loup. Can TR6-f e un tbe soiid phase block an autocrine
loup? We are net aware uf any example in an experimentai system
that this can be achieved. Because a ccli is a three-dimensional
entity, sohd-pbase TR6-f e can only interfere with a part ofthe ccli
surface that bas contact with the weii. Therefore, the sulid-phase
TR6-f e cannut prevent the interaction between a putative soluble
suppressive autocrine and LIGI-iT on must parts ofthe ccli surface
that are net in contact with TR6-fc. Consequently. must LIGHT
molecuies un a cdl surface shuuid stili rcccive negative signais
frem the putative suppressive autocrine, if there is une. Therefore,
it is vcry difficult tu expiain the positive effect ofsolid-phase TR6-
Fc. In addition, if soiid phase TR6-fc wcre tu interfere with tbe
negative regulatory loup by leaking itseif into solution, TR6 with
eut Fe (hkcly monumers) should be more efficient te do so, and
cunseqtientiy enhance T ccli proliferation better than TR6-Ec. This
vas obvieusiy not the case. because wc shuwed that TR6 without
fc en sohd phase even failed tu effectively augment T ceH prolif
eration (Fig. 1H). The iow efflciency cf TR6 withuut Fc in this
experiment might be due te its munomer format, which is less
potent in cross-Iinking LIGHT than the dimeric format cf TR6-Ec.
Data from hterature do not support the negative ioep theety. lt bas
been shuwn that L1GHT transgenic mice overcxpressing LIGHT
un T cclls have enhanced immune respense (39, 40, tu be detailed
in the next paragraph). Ibis result dues net fit tu thc medel in
whicb LIGHT transduces negative signais intu T ceils, because if
su, thc LIGHT transgenic mice shuuld have suppressed immune
response instead. Lastiy. there are —4—5 TNf famiiy mcmbers
capable of transducing signais intu ceiis, but none of thcm trans
duces a negati\c ene. Based un these arguments, it is cenciuded
tbat TR6 excrts ils effect by stimuiating T cefls via LIGI-IT, but flot
by interfering with a putative negative autocrine luop.
As mentiuned abeve, LIGHT uverexprcssiun in the T ceH cern
partment in LIGHT transgenic mice rcsuits in prefeund inflamma
tion and develepment of auteimmune syndromes (39, 40); T cefls
overexpressing LIGHT have an activatcd phenutype (39). Proba
biy. such up-regulated immune respense uf T cefls is due te stim
ulation of TR2/Hempesvirus entry mediator un dendritic celis by T
celI-derived LIGI-IT, and the dendritic ceils in turc augment T ccli
activiW; TR2 on T cefls can also reccive LIGHT stimulation di
rectly from their fellew T ceils (40). l-Iewcvcr, it is entirciy pos
sible that overexpressed LIGI-IT un thc T cefls receives stimulation
rcverscly from TR2 expressed en uther T ceiis, and such stimula
tion augments their rcsponsivencss tu TCR hgatien.
What is the biolegical significance ef reverse signahng thruugb
LIGHT? We found that the reverse signaling tbreugh LIGHT pref
erentialiy premutcs Thi but net Th2 ccli cytukinc production. In
agreement with this finding, a reccnt report demenstrated that mu
cosal T celis everexpressing LIGFIT show enhanced Thi cytekine
production (39). Because CTL differentiation dcpcnds un Thl cy
tokines, it is net sumprising that CIL activity tvas augrnented after
custimulation tbruugh LIGHT by TR6-Fc. It is werth mnentiening
that soluble LIGHT inhibitcd CTL activity (without TR6-Fc stim
ulation) (Fig. 5C). Ibis finding tinderscores the importance of
LIGE-II costimulatiun in CIL develupment. I-Iarrup et al. (41) no
ticed that et an intermcdiate concentration LIGI-IT premotes MLR.
but it fails to do su et a higbcr concentration (10 g/mi). Such a
biphased respense probabiy rcflects e shift from custimulation
through TR2 by soluble LIGHT tu inhibition uf TR2-LIGHT
bidirectienal custimulation, depending un the concentration cf
LIGI-IT. Ibis result is consistent with our reverse signaiing theoiy
and flndings. Wc specuiate tbat in vivo, the biuiogicai fonction ef
endugenous soluble LiGHT. whicb comes frem cdl surfaces after
shedding (9), might be stimuiatomy or inhibitory, depending on ils
local concentration and status cf aggregatiun. Because dendritic
cclls aise express LIGHT, TR2 un the T ccli surface migbt activatc
dendritic ceils through LIGI-IT tu modtilate their APC function. If
se, this will represent e new mechanism fer T ccli and dendritic
ccli interaction and cooperation. In tbis study, we used recombi
nant TR6-f e as an artificiel binding partner for LIGHT. In vive,
molecuies that can trigger LIGHT signaiing are probably ceH
surface TR2 or LTf3R. The endegcnous TR6 might act as an
inhibitor tu the bidirectional cestimulatien behveen TR2 and
LIGHT, or fonction as a custimtmlating facter tu LIGHT, dcpending
en wbcther il cxists as munemers, or as trimers like other cdl
surface TNFR family membcrs. This aspect is worth ffirthcr
investigation. If the endogenous TR6 functiens as an inhibitur,
thcn gastreintestinai tumers secreting TR6 viIl certainly gain
survivai advantage by interfering with y as weii as a T ccli
CIL activitics.
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Our stcidy rcvealcd a nove! phcnomcnon of reverse signaling
through a ce!! surface TR6 ligand, most !ikely LIGI-IT. Increasing
cases of such bidircctiona! signal transduction between receptors
and ligands have bccn found in biologica! systems. We can takc
advantage of such a phenomenon by using a soluble ligand (or
receptor) to b!ock signaling in both directions and thus modulate
biologica! responses. However, we must be aware that soluble li
gands (or receptors) vill necd to be monomer without aggrcgation
or ce!! surface anchoring capabilities to be reliable antagonists, or
cisc they wi!! become agonists for one of the directions.
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Abstract DcR3/TR6, a secreted protein, isa member ofTNF receptor family. Its Iigands include FasL, LIGHT, and
TLA, ail TNF family members. TR6 can interfere with FasL- or LTR-mediated apoptosis; t can also inhibit T-ceII
costimulation by blocking the two-way signaling between TR2 and LIGHT, and the one-way signaling from TL A to DR3.
In this study, we discovered that 1R6 was secreted by peripheral blood mononuclear ceils tPBMC) stimulated by T-cell
mitogens. It inhibited actin polymerization of T celis upon mitogen stimulation, and repress T-cell pseudopodium
formation, which is known to be important for cell—celi interaction. As a consequence, T-cell aggregation stimulated by
alloantigens, anti-CD3 or PHA was suppressed by either soluble or solid phase TR6-Fc. This resu It suggests that TR6 might
regulate T-cel I interaction with other cel Is such as antigen-presenting cel Is (APC) or their fellow T ceils by preventing them
from forming inseparable ccli clusters, which are undesirabie for the progression of immune responses. J. Celi. Biochem.
89: 603—61 2, 2003. © 2003 WiIey-Liss, Inc.
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DcR3/TR6, a soluble factor due to its lack of
the transmembrane domain, belongs to the
TNFR family. TR6 can hind to TNF family
members FasL [Pitti et al., 1998], LIGHT [Yu
et al., 1999], and TL1A [Migone et al., 2002].
Binding of TR6 to FasL blocks Fas-mediat
ed apoptosis. Moreover, since LIGHT and its
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receptor HveA trigger bi-directional costimula
tion of T ceils [Zhang et al., 2001; Shi et al.,
2002], LIGHT bindingby TR6 can interfere with
such costimulation and consequently inhibit
T-cell activation [Zhang et al., 2001]. Similarly,
the interaction between TR6 and TL1A disrupts
T-cell costimulation by TL1A through its recep
tor DR3 [Migone et al., 2002], and resuits in
abated T-cell responses [Migone et al., 2002].
Due to probably a combination ofthese mechani
sms, in vivo administration of TR6 reduces
graft-versus-host diseases, and inhibits heart
allograft rejection [Zhang et al., 2001]. It is
conceivable that TR6-secreting tumors utilize
these mechanisms to avoid apoptosis, and
that TR6 plays an importance regulatory role
in normal immune responses.
In the course of our study on the immune
regulatory role of TR6, we found that TR6
secretion by leukocytes was significantly en
hanced during mitogen activation of T celis. In
the presence of soluble or solid phase TR6, T
celis could no longer form typical clumps upon
mitogen stimulation, and their pseudopodium
formation was inhibited. These findings re
vealed a so-far undocumented TR6 function on
T celis.
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MATERIALS AND METHODS
Recombinant Proteins
The preparation of recombinant proteins
TR6-Fc, TR6, and TR11-Fc was described in
our previous publication [Zhang et al., 2001].
TR11 (GITR) [Ronchetti et al., 2002] and Fc
fusion protein TRi 1-Fc had no effect on T-cell
aggregation, compared with PBS or normal
human IgG, and was thus used as a control
protein for TR6-Fc.
Lymphocyte Preparation and Culture
Peripheral blood mononuclear ceils (PBMC)
were prepared by Lymphoprep gradient
(NYCOMED, Oslo, Norway), and T ceils were
obtained from PBMC by sheep red blood celi
rosetting [Luo et al., 1993], orby negative select
ion (deletion ofcells positive for CD11b, CD16,
CD19, CD36, and C056) with magnetic beads
according to the manufacturer’s instructions
(Miltenyi, Auburn, CA).
Mouse spleen celis were prepared by lysing
red blood ceils ftushed out of the spleen [Luo
et al., 2001]. Spleen T celis were purified by
deleting 1g-positive and adhesion ceils with T
ceil columns according to the manufacturer’s in
structions (Cedarlane, Hornby, Ont., Canada).
Ail ceils were cultured in RPMI 1640 sup
plemented with 10% FCS, L-glutamine, and
antibiotics. RPMI 1640, FCS, penicillin—strep
tomycin, and L-glutamine were purchased
from Life Technologies, Inc. (Burlington, Ont.,
Canada). 3H-thymidine uptake was measured
as described previously [Luo et al., 1993; Luo
et al., 2001].
Mixed lymphocyte Reaction (MIR)
For human MLR, PBMC were isolated from
two healthy volunteer donors (donors A and B).
PBMC from donor B were pre-treated with
mitomycin C, and were used as stimulators.
The celis from donors A and B were then mixed
at 1:1 ratio and cultured at a final concentration
of S x 106 cells/2 ml!well in 24-well plates.
Ceils from donors A and B were also incubated
alone as controls. For mouse MLR, BALB/c
spleen ceils were pre-treated with mitomycin C,
and were used as stimulators. C57BL/6 and
BALB/c spleen celi were then mixed at 1:1 ratio,
and cultured in 24-well plates at 8 x 106 ceils!
2 ml/well.
TR6 ELISA
Anti-TR6 mAb (clone 17B07) was described in
our previous publication [Zhang et al., 2001].
The TR6 polyclonal antibody was purified from
antisera generated from rabbits immunized
with four synthetic peptides that spanned the
TR6 protein sequence: V30-R46, R64-Q89,
E240-R258, and R284-L297 (amino acid posi
tions were relative to the start methionine).
Rabbit antisera were purified on a TR6-coupled
Affi-GellO column. The specificity of the TR6
polyclonal antibody was demonstrated in the
ELISA by testing cross-reactivity to recombi
nant OPG and HveA, the two TNF receptor
family members most closely related to TR6.
Neither OPG nor HveA was detectable in the
TR6 ELISA. The preparation of recombinant
TR6 was described in detail previously [Zhang
et al., 2001]. The protocol of TR6 ELISA is as
follows. Ninety-six-well Nunc Maxisorb plates
were coated overnight with anti-TR6 mAb in
0.05 M NaHCO3 buffer (3 tg/ml, 100 p.l/well) at
4°C. After washing with buffer A (PBS contain
ing 0.1% Tween-20), the plates were blocked
with 3% BSA in PBS (250 pi/well) for 1 h at
room temperature. Serum samples were diluted
when necessary in buffer B (PBS containing
0.1% Tween-20 and 1% BSA), and incubated
overnight in the mAb coated plates at 4°C. The
plates were washed and reacted with biotiny
lated rabbit anti-TR6 Ab (0.125 tg/ml in buffer
B, 100 il/vell) at room temperature for 2h. They
were then washed and reacted with streptavi
din-peroxidase (1:2,000 v/v in buffer B, Vector
Laboratories, Burlingame, CA). After additional
washes, a freshly prepared color development
mixture (1:1 v/v mixture of tetramethyl benzi
dine solution and H202 solution, TMB Micro
well Peroxidase Substrate System, Kirkegard &
Ferry, Gaithersburg, MD) was added to the
plates (100 tl/well). The reaction was stopped
after 20 min at room temperature with 0.1 N
H2$04 (100 iil/well), and 0D450
,
was subse
quently measured. Recombinant human TR6
was used as standards. ELISA sensitivity was
below 10 pglml.
Flow Cytometry and Confocal Microscopy
Human T ceils were cultured overnight in the
presence ofTR6-Fc. They were reacted with 1 ig
anti-CD3 in 100 jil cold PBS for 30 min on ice,
and after washing, with 0.5 ig of goat anti
human IgG for another 30 min. The cells were
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then washed with cold PBS, and transferred to
warm PBS at 37°C for 5 min. For F-actin
staining, 1 x 106 of the CD3-crosslinked T ceils
were fixedwith 3.7% formalin for 30 min atroom
temperature and stained with Alexa Fluor-488-
conjugated phalloidin (Molecular Probes,
Eugene, OR). The celis were analyzed with a
Coulter Epics-XL ftow cytometer and a confocal
microscope. Digital images were processed with
Photoshop (Adobe, Seattie, WA).
RESU LIS
Human PBMC Secrete TR6 After
Mitogen Activation
Although TR6 is produced by some tumors, its
possible secretion by leukocytes has not been
investigated. As our recent study showed that
TR6 could regulate T-cell activation and in vivo
immune responses [Zhang et al., 2001], it is
logical to ask whether leukocyte could secrete
TR6. We developed sensitive ELISA for this
purpose. Human PBMC were cultured in the
absence or presence of a mitogen, PHA, and TR6
was measured in the supernatants after 48 h.
TR6 was detectable in unstimulated culture at
about 100 pg/ml. With PHA (2 jig/ml) stimula
tion, the TR6 level showed a sixfold increment,
and reached 620 pg/ml (Fig. 1), suggesting that
leukocyte-secreted TR6 might participate in
immune regulation.
TR6 Inhibits Leukocyte Aggregations in MIR
During our study of TR6’s effect on T-cell
activation, we noticed, unexpectedly, that solu
7M
600
500E400
300
2O0
iOo
Medium
Fig. 1. TR6 s secreted by activated T celis. Human peripheral
blood mononuclear celis CPBMC) were cultured for 48 h in 24-
well plates at 4 x 106/2 ml/well in the presence of PHA 12 pg/ml).
The culture supernatants were harvested and tested for TR6 levels
by ELISA. The means + SD of duplicate samples are shown. The
experiments were performed more than twice, and results from a
representative one are shown.
ble TR6 strongly inhibited ceil aggregation in
the MLR. As illustrated in Figure 2A, human
PBMC from donors A or B alone showed no
apparent aggregation in culture. In MLR, the
ceils formed clumps, starting from 6 h and last
ing for up to 6 days. Soluble TR6-Fc (10 ig/ml)
completely suppressed clump formation at 16 h.
The suppression was obvious at about 6 h after
the initiation of culture when untreated MLR or
a control recombinant protein TRi 1-Fc-treated
MLR started displaying clumps and lasted for at
least 72 h (data not shown).
Human TR6-Fc was also effective in inhibit
ing clump formation of mouse MLR, as depicted
in Figure 2B. This was not surprising because
human TR6 binds mouse LIGHT and FasL
[Zhang et al., 2001].
TR6 Directly Prevents T Celis From
Aggregation Formation
We next tested whether TR6 could inhibit
clump formation when T ceils were activated by
mitogens other than alloantigens. When PBMC
were stimulated by PHA (0.2 figIml) or anti-CD3
(0.5 jig/ml), they readily formed clumps in 4 h,
and the clumps lasted for 3—5 days. Figure 3A
documents dumping at 16 h. Clump formation
was significantly inhibited in the presence of
TR6-Fc (10 jg/ml), but a control fusion protein,
TR11-Fc, had no such outcome. To prove that
the effect occurred directly on T celis but not via
other celi populations in PBMC, purifled T celis
were similarly treated with PIlA in the presence
or absence of TR6-Fc (Fig. 3B). Again, TR6-Fc
but not TR11-Fc drastically suppressed the ceil
clustering, suggesting that TR6 acts directly on
T celis to prevent their aggregation upon
mitogen stimulation.
Anti-Aggregation Effect Can 5e Achieved by Solid
Phase TR6, and is Likely Mediated by LIGHT
TR6 can bind to FasL and LIGHT, both of
which are capable of reverse signaling [Suzuki
and Fink, 1998; 5h et al., 2002]. To identify
which of the two was involved in mediating the
inhibitory effect on T-cell aggregation, soluble
LIGHT and Fas were tested as blocking
reagents. Like soluble TR6-Fc, TR6-Fc on solid
phase via plate-bound goat anti-human IgG
inhibited T-cell aggregation (Fig. 4). Soluble
LIGHT (10 pg/ml) but not Fas (10 tg/m1)
potently neutralized the inhibitory effect of
solid phase TR6, while LIGHT by itself had
no influence on ceil aggregation. These data
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Fig. 2. TR6-Fc nhibits mononuclear ccl) interaction in the
mixed lymphocyte reaction (MLR). Human MLR (A) or mouse
MLR (B) wasperformed in thepresenceoflR6-Fc )MLRÎFR6-Fc) or
a control fusionproteïnTRl I -Fc (MLR/TR1 1 -Fc), hoth at 10 pg/ml,
as indicated. Photos were taken 16 h after culture. For human
MLR, PBMC from donors A alune, B alune, or a mixture ut; buth
(MLR( atthe 1:1 ratio (4 x 1 Ot- ccl ls/2 m)/wc)l foreach dunur) were
cu)Iured in 24-wel) plates. Fur muuse MIR, spleen cells (rom
C57BL/6 alune, or a mixture ut; CS7BL/6 and BALB/c spleen cells
(MLR) at the 1:1 ratio, were cultured in 24-well plates (4x106
cells/2 ml/well foreach strain). Human donurB PBMC and BALB/c
spleen cells were pretreated with mitomycin C before MLR.
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Fig. 3. TR6-Fc inhibits PBMC and T-ceIl aggregation induced by mitogen stimulation. Human PSMC (A) orpurified T celis (B) were cultured n 96-welI flat-bottomed plaies ai 4 z io cel(s1200 pl/well. PHA (0.2 tg/
ml), anti-CD3 Ah (0.5 pg/ml), TR6-Fc (10 pg/ml), and TRi 1 -Ec (10 pg/ml) were present as indicated. Photos
were taken 4 h aber culture.
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Fig. 4. Effect of solid phase TR6-Fc, soluble Fas and soluble
LIGHT on T-cell aggregation. To prepare solid phase TR6-Fc,
NUNC 96-well-plates were coated overnight at 4°C with 5 pg/ml
goatanti-human lgG (Southern Biotechnology, Birmingham, AL)
in PBS at 50 pl/well. After washing, the plates were incubated
with TR6-Fc or TRi 1 -Pc (hoth at 10 pg/ml) in P85 aS 37°C for 2h.
T cells were cultured in these wells in the presence of PHA
(0.2 pg/ml), soluble Pas (5 pg/ml), or soluble LIGHT 15 pg/ml), as
indicated. Photos were taken 48 h after culture. Uncoated: wel s
were not coated with any reagents; TR6-Ec-coated: wells were
i’Rô-Fc coated
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coated with goat anti-human lgG followed by TR6-Fc; uncoa
ted— LIGHT: T cells were cultured in uncoated wells in the
presence of soluble LIGHT; uncoated — PHA: T cells were
cultured in uncoated wells in the presence of PHA; TR6-Fc-
coated — PHA: cells were cultured in TR6-Pc-coated wells in tbe
presence of PHA; TR6-Fc-coated —* PHA + Pas: cells were
cultured in TR6-Ec-coated wells in the presence of PHA and
Pas; TR6-Fc-coated — PHA + LIGHT: cells were cultured in TR6-
Fc-coated wells in the presence of PHA and LIGHT.
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i’R6-Fc coated PilA i’kô-Fc coated -, PilA + Fas
TR6-Fc coatcd PilA + LIGHT
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suggest that LIGHT mediates the effect ofTR6
in preventing T-cell aggregation.
TR6 Inhibits Actin Polymerization and
Pseudopodium Formation of T Celis Upon
T-CeII Receptor (TCR) Ligation
T-cell aggregation upon mitogen stimulation
is a process requiring cytoskeleton reorganiza
tion followedby cellular morphological changes.
We examined the actin polymerization of T celis
with TR6 pre-treatment. T ceils were cultured
overnight in the presence ofTR6-Fc or TR11-Fc
(both at 10 pg/ml) in serum-free medium, and
then crosslinked with anti-CD3. The actin
polymerization of these ceils was analyzed by
phalloidin staining using flow cytometry, and
cell morphology was examined under a confocal
microscope. The actin in T celis activated by
CD3 crossiinking rapidiy underwent polymer
ization as evidenced by a significant increase in
the intensity of phalloidin staining accompa
nied by protrusion ofpseudopodia within 5 min
(Fig. 5). TR6 pretreatment strongly inhibited
the increment ofphalloidin staining (Fig. 5A,B),
and pseudopodium formation also was re
pressed (Fig. 5B,C). Thus, TR6 pre-treatment
likeiy affected an event upstream of actin
polymerization, and this might be responsible
for the observed inhibition ofT-cell aggregation.
DISCUSSION
In this study, we reported, for the first time,
that TR6 was secreted by leukocytes after T-cell
activation, and revealed a previously undocu
mented function of TR6 in regulating T-cell
interaction with other leukocytes.
Celi aggregation during T-ceil activation was
inhibited by soluble and solid phase TR6.
However, T-cell proliferation was enhanced in
the presence of soiid phase TR6 in combination
with suboptimal TCR ligation [Zhang et al.,
2001], indicating adequate T-cell activation
under such conditions. During T-celi activation,
essential signais are transduced into ceils
within several minutes [Gil et ai., 2002]. The
inhibition of T-celi aggregation severai hours
after their activation did not interfere with
their proliferation, impiying that the normaily
observed T-cell aggregation after mitogen sti
mulation in in vitro culture is not an essential
part of the activation program.
The likely mechanism of TR6’s inhibitory
effect on T-cell aggregation is reverse signaiing
through LIGHT. Ceil surface LIGHT, and
several other TNF family members, such as
CD4OL [Van Essen et al., 1995], CD3OL [Wiley
et al., 1996; Cerutti et al., 2000], TNF-Œ [Eissner
et al., 2000], TRANCE [Chen et al., 2001], FasL
[Suzuki and Fink, 2000; Suzuki et al., 2000],
and TEAIL [Chou et al., 2001], can transduce
signais into T ceils [Serrador et al., 1998]. We
recently found that crosslinkingofLlGHTleads
to inhibition of p38 IVIAPK activation and actin
polymerization in T ceils upon chemokine
stimulation (data not shown). This is in keeping
with the inhibitory impact of TR6 on T-celi
aggregation, since such an effect aiso depends
on actin polymerization. Currentiy, there are
three known TR6 ligands, i.e., LIGHT, FasL,
and TL1A. Since TL1A is mainiy expressed
on endotheliai celis [Migone et al., 2002], but not
on T celis, it is not relevant to this study. We
tested soluble Fas and LIGHT as competitors to
soiid phase TR6 to assess their invoivement.
Soluble FasL was not used for this purpose
because of its potentiai apoptosis-inducing
effect on activated T celis. LIGHT but not Fas
reversed the TR6 effect, suggesting that TR6
inhibits T-celi aggregation via LIGHT reverse
signaling. We cannot totally exciude the possi
bility that a so-far uncharacterized TR6 iigand
X on T-celi surface aiso mediates the anti
agression effect of TR6, but this ligand X and
LIGHT must have an identical binding site to
TR6, and consequentiy LIGHT can competi
tively inhibit ligand X’s binding to TR6. How
ever, evidence for the existence ofsuch a ligand
is lacking.
We showed that, iike soiid phase TR6-Fc,
soluble TR6-Fc was also capable of preventing
T-cell aggregation. It is possible that only low
degree crosslinking of TR6 ligands by dimeric
TR6-Fc or the aggregated form of TR6-Fc in
solution is sufficient to trigger such an effect.
T-celi actin polymerization was inhibited
downstream of ligand engagement by TR6-Fc.
Such inhibition was probabiy a cause ofrepres
sed T-ceil pseudopodium formation. The signal
ing pathway through which TR6 affects actin
poiymerization is currentiy under investiga
tion. It has been reported that the formation of
uropods, which are rear-end pseudopodia, is
essentiai for T-cell aggregation after mitogen
stimulation [Serrador et al., 1998]. Thus, the
reduced formation of pseudopodia in TR6-
treated T ceils iikely contributes to poor forma
tion ofT-celi aggregation.
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Fig. 5. TR6-Fc inhibits anti-CD3-induced T-cell aCtin poly
merization and pseudopodium formation. T ceils were cultured
overnight in medium in the absence (Med ON), or presence of
TRi 1 -Fc (TRi 1, ON; 10 pg/ml) or TR6-Fc (TR6, ON; 10 ag/ml).
Afterwashing, the colis were crosslinked with anti-CD3 for 5 mm,
as indicated. Ail the experiments were performed more than
twice, and results from a representative one are shown. A: Flow
cytometry analysis of F-actin. F-actin staining of T ceils culWred
overnight in medium without anti-CD3 simulation was used as a
negative control, with its F-actin intensity (shaded area) set at 0%.
F-actin staining (solid unes) of ceils receiving different pre
treatments followed by anti-CD3 crosslinking s shown. Percen
tage of ceils positive for F-actin staining above the control
staining is shown. AIl three panels are in log scale. B: Confocal
microscopy of T-cell morphology. The same set of T cells, as
described in (A), was examined by confocal microscopy.
C: Quantitative assessment of T-cell pseudopodium formation.
The cells in (B) were quantified for pseudopodium formation.
Three randomly selected view fields (containing about 80—100
cel Is per field) per sample were examined, and the means ± SD of
the percentages of pseudopodium-positive celis among total
cells of the three flelds are shown.
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What is the physiological significance ofTR6
inhibitingT-cell aggregation? When T-cell activ
ation is initiated, T ceils in lymphoid organs
need to interact with antigen-presenting celis
(APC). In addition, close T cell—T ceil coopera
tion is also required for optimal CD4 responses
and for C04 celis to help CD8 cells through local
lymphokine secretions. Such T cell—T cell co
operation has been reported in the case of
LIGHT and HveA [Tamada et al., 2000],
members of TNF and TNFR families, respec
tively, which are both expressed on T ceils, and
their interaction leads to optimal T-cell
responses. A recent study has shown that T
cells recognizing the self-MHC present
increased response to foreign antigens [Wulfing
et al., 2002], and obviously, the self-MHC could
be ones from a fellow T ceil. This validates the
concept of T cell—T cell collaboration. However,
the T cell—APC and T cell—T cell interactions
need to be terminated once their purposes are
served. Probably, TR6 secreted by T celis helps
to dislodge, or prevent T celis from having
prolonged engagement with APC and/or other
T ceils. In in vitro culture, endogenous TR6 in
the supernatant reached 620 pg/ml, but cell
aggregation was not inhibited. It is possible
that a higher TR6 concentration is required,
because exogenous TR6 at 10 .tg/ml was needed
for such an effect. In lymphoid organs in vivo,
T cells are tightly packed at a density much
higher than in in vitro culture. Therefore, TR6
concentration high enough to dislodge T celis
from APC or other T celis is probably achievable
locally.
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III. Discussion
In this project, the role of TR6 in immune regulation was investigated. In the mouse system,
soluble TR6 suppressed IL-2, IL-5 and GM-CSF secretion by mitogen-activated T celis, and
downregulated cytotoxic T-cell activity in vitro. In vivo, soluble TR6 could suppress the
graft versus host disease (GVHD) and allograft rejection. In the human system, solid phase
TR6, in the presence of suboptimal soÏid phase anti-CD3, significantly costimulated T celis
in terms ofproliferation and cytokine production. Blocking studies using soluble LIGHT and
Fas indicated that LIGHT likely mediated the costimulation. This has revealed a novel
mechanism of TR6 in triggering reverse signaling through a ligand, LIGHT. Based on this
finding, it is Iikely that the suppressive effect of soluble TR6 in the mouse system is, in part,
due to its interference with the two-way costirnulation between HveA and LIGHT.
Intriguingly, soluble TR6 augmented T-cell proliferation, lymphokine production and
cytotoxic T-cell activity in the human system. The opposite effects of soluble TR6 in the
human and mouse systems are probably due to different affinity of TR6 to human and mouse
LIGHT (to be elaborated beÏow). We also found after T-cell activation, T ceils augmented
their TR6 secretion. Interestingly, both soluble and solid-phase TR6 were able to suppress
mitogen-induced T-celÏ aggregation. T ceils pretreated with TR6 had reduced actin
polymerization and pseudopodium formation, which are both important for the celi-celi
interaction. These resuits suggest that TR6 might regulate the duration of T-cell interaction
with other celis, and allow T cells to disengage from antigen presenting ceils or neighboring
T celis once the interaction becomes unnecessary.
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111.1. Monomer TR6 withottt aggregation is reqtdred to inhibit hurnan T-cetl responses
Our findings have confirmed one of our hypotheses that the inhibitory effect of human TR6
in the mouse system shouïd be attributed to TR6’s interference with the bi-directional
costimulation between HveA and LIGHT. However, how do we explain the seemingly
opposite effects of soluble human TR6-Fc on human and mouse T-cell responses? In the
mouse system, soluble TR6-Fc inhibited CTL in vitro and allograft rejection in vivo. In
contrast, in the human system, soluble TR6-Fc actually enhanced T-cells proliferation,
cytokine production, and CTL activity. Theoretically, such a difference miglit be caused by
the Fc tau ofthe recombinant protein. As the Fc tau used is ofhuman IgG1 origin, it can bind
human fc’R on B celis and monocytes/macrophages. Consequently, the soluble TR6-fc in
the human system might become membrane-bound, and costimulate T celis via the reverse
signaling through LIGHT. On the other hand, human IgGi does not bind well to mouse fcyR,
and remains in solution. This allows it to block the two-way costimulation between LIGHT
and HveA. However, the Fc portion of TR6-Fc and other Fc-containing recombinant proteins
(including the control recombinant proteins) used in our study was mutated to elirninate its
FcyR binding capability. We confirmed that TR6-fc did not bind to human or mouse fcyR
bearing celis (data flot shown). Therefore, there lias to be another explanation for the opposite
effects of TR6-fc in the hurnan and mouse system. As TR6-fc is a dimer, and it might also
form aggregates in solution like any other proteins, it may play a dual role in solution: as an
inhibitor blocking the bi-directional interaction between HveA and LIGHT, or as a co
stimulator cross-linking LIGHT. The former inhibits T-cell responses and the latter enhances
it. The end-result should be the sum of these two opposite effects, which may have different
affinity requirements. In the human system, the higher affinity between TR6-fc (dimers, and
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possibly some aggregated form) and LIGHT might result in sufficient LIGHT cross-linlcing
and consequently costimulation, and this effect might ovenvhelm the possible TR6 effect on
the interference of the LIGHT and HveA interaction. In the mouse system, the putative lower
affinity between human TR6 and mouse LIGHT might not be sufficient for LIGHT cross
linking, but TR6-Fc can stili interfere with the interaction between HveA and LIGHT. In this
case, the blocking effect overwhelms the effect of crosslinking, hence downregulating the T
celi response. Further studies are needed to examine this hypothesis. If this is true, we have
to use oniy the soluble monomer form of TR6 without aggregation for the purpose of
downregulating human T-cell responses in therapeutic applications.
111.2. The biologicat significance of TR6’s inhibition on T-cell aggregation
We have shown that TR6 strongly inhibited T-cell aggregation. This inhibition was
accompanied by suppression of actin poÏymerization, and T-cell pseudopodium formation.
Interestingly, we found that whule T-cell-T-cell interaction was inhibited, T-cell proliferation
was flot. This suggests that the T-cell aggregation we observe in vitro during mitogen
stimulation is not a necessity, at least not a necessity for the later part ofT-cell activation. In
vivo, after T-cell activation, which might only require several minutes (Gil et al., 2002), the
activated T cells need to dissociate from APC or neighboring T celis to disseminate into
circulation for their effector function; TR6 secreted locally by activated T celis might serve
this purpose.
111.3. The in vivo role of TR6 in immune responses
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We have shown that activated lymphocytes secreted TR6. What is the function of such
endogenous TR6 in immune responses in addition to terminating T-cell aggregation as
discussed above? The answer is highly dependent on the format of the secreted TR6, i.e.,
monomers, or trimers as other surface TNfR family members, or aggregates. If it is in the
form of monomers, then the overail effect of TR6 should be suppressive to immune
responses, because it can conceivably inhibit the two-way costimulation between FasL and
Fas (Suzuki et aÏ., 2000), and between LIGHT and HveA; it might also repress the
stimulatory effect ofTL1A to DR3 on T ceils. We believe this is the likely scenario, because
it fits to our perception that TR6-secreting tumors use this molecule to downregulate tumor
surveillance, and it is compatible with our results with the mouse system. $uch
downregulation by TR6, which is secreted after the activation is achieved, in an immune
response might be one of the built-in check-and-balance mechanisms in the immune system
to reign in or to terminate on-going immune responses. On the other hand, if the endogenous
TR6 is a trimer or easily forms aggregates which are capable of crosslinking LIGHT or FasL
and trigger their reverse signaling, it might have an enhancing role in the immune response.
Obviously, our next task is to determine the format of endogenous TR6 to fully understand
its role in immune regulation.
In the mouse model, in vivo administration of human TR6 led to downregulation of GVHD
and allograft rejection. We initially attributed these effects mainly to the blocking of
stimulation from LIGHT to HveA. Our subsequent finding of the reverse costimulation
through LIGHT suggests that TR6 could block the two-way costimulation between LIGHT
and HveA. However, these are not the only mechanisms involved. Recent study by Migone
et al., has shown that TL1A, which is mainly produced by endothelial celis, can bind to DR3
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and enhance T-cell response to IL-2 (Migone et al., 2002); TR6 can bind to IL1A and
repress the enhanced T-cell response. It is possible that during allograft rejection, local
inflammation stimulates TLIA secretion by endothelial celis, and the administered TR6
blocks the effect of TL1A in enhancing T-cell responses. This could be an additional
mechanism for the observed effect ofTR6 in vivo (Shi et al., 2003, in press). Moreover, we
recently discovered that TR6 could also inhibit T-ceIl chemotaxis in vitro and in vivo. Such
an effect could also play a role to prevent T ceils migration to the alloantigen site in the
activation and effector phases. In addition, blocking of FasL and Fas interaction by TR6
could in theory inhibit T-cell costimulation via fas (Suzuki et al., 199$), or reversely via
fasL (Suzuki et al., 2000); it rnight protect vascular endotheliaÏ celis from fas-mediated
apoptosis during graft rejection (Akyurek et al., 1998). Therefore, the in vivo beneficial
effects ofTR6 during allograft rejection are multifaceted.
In spite of the possible multiple effects of TR6 on T-cell function, prolongation of allograft
survival with in vivo administration of TR6 in mice was moderate. Several factors might be
responsible for this. First, the half-life of the TR6-Fc used was only about 20 min (data flot
shown). Such a short haif-life is mainly due to the insect celi origin ofthe recombinant TR6-
fc, with an unusually high content ofmannose. According to our calculation, within 4 h (12
half-lives) after TR6 administration, the serum TR6 level is below the effective in vitro
concentration (10 p.g/ml). Therefore, for most part of the day, the recipient is under no
protection from this immune modulator. Secondly, LIGHT and HveA two-way costimulation
is only one of the costimulation pathways T ceils use to achieve full activation. Many other
costimulation pathways such as CD28 (Chen et aÏ., 1992), OX-40 (Godfrey et al., 1994),
CD4O (Dune et al., 1994), 4-1BB (Shuford et al., 1997), are flot blocked. Moreover, strong
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TCR stimulation, such as that triggered by alloantigens is probably less dependent on
costimulation (Wang et al., 2000). Conceivably, a combination of these factors led to the
moderate prolongation of graft survival. In the future, TR6 with a longer haif life will be
better in a drug combination rather than as a stand-alone medication to achieve
immunosuppression. TR6’s effect on inhibiting Fas-mediated apoptosis suggests that it miglit
be more useful in treating chronic rejection, in which vasculopathy caused by fas-mediated
apoptosis of endothelial celis and vascular smooth muscle ceils plays a major role (Akyurek
et aï., 1998).
111.4. TR6 in tunzorigenesis
Tumor ceils might produce many immunosuppressive factors, such as TGF-, IL-10,
DF3/MUC1, in order to obtain survival advantages (Gimmi et al., 1996). TR6 could be
another immune modulator, as this gene has increased expression in some malignant tissues
(Pitti et al., 1998) and its protein product is over-expressed in human adenocarcinomas ofthe
esophagus, stomach, colon, and rectum (Bai et al., 2000).
Is the overexpression of TR6 in tumors a consequence of malignancy, in which chaotic gene
amplification occurs, or causative of tumorigenesis? It is evident that some tumor ceils have
TR6 gene amplification (Oshima et aï., 2000; Mild et al., 2002). But another report lias
shown that tumors overexpress TR6 without gene amplification (Bai et aï., 2000). Recent
studies in our laboratory have shown that TR6 gene amplification could be observed in about
40% of liver carcinomas but not in gastric carcinomas (Wu et al., 2003), in spite of TR6
overexpression in 70-80% of these turnors. This indicates that different types of tumors have
different mechanisms to upregulate TR6 expression, and in most cases, upregulation is flot
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the consequence of gene amplification, hence unlikely the consequence of rnalignancy. Then,
does TR6 have a causative role in tumorigenesis?
TR6 interacts with FasL, LIGHT, and TL1A and can block Fas-, LTR- and/or DR3-
mediated apoptosis (Zhang et al., 2001, Shi et aÏ., 2002; Migone et aÏ., 2002). Thus, TR6
might protect turnor ceils from apoptosis mediated by these molecules. As DR3 is rnainly
expressed in lymphoid ceils and some other ceils of hematopoietic origin (Migone et al.,
2002), TR6’s effect on DR3 in relation to tumorigenesis might be restricted to some
leukemia. In our study, we have demonstrated that TR6 interferes with the interaction
between LIGHT and HveA, and inhibits their bi-directional costimulation of T celis.
Additionally, Hsu (2002) reported that soluble TR6 regulates dendritic celi differentiation,
which, in retum, drives T ceils into the Th2 phenotype. Moreover, a recent study from our
laboratoiy bas demonstrated a novel function for TR6 in inhibiting T-cell chemotaxis in vitro
and in vivo in mice (Shi et aÏ., 2003, in press). The relevance of such an effect in
turnorigenesis is evidenced by our finding that gastric turnor patients with high serum TR6
levels had lower levels of infiltrating lymphocytes in the tumor mass (Wu et al., 2003). It is
conceivable that such an effect will reduce the chance of T ceils to interact with turnors both
during activation and effector phases. These TR6 effects on T cells rnight collectively
dampen the immune surveillance in vivo. We propose the following model for the role of
TR6 in tumorigenesis: fast proliferating cells, such as epithelial cells or hepatocytes in liver
cirrhosis, undergo malignant mutation by chance, and at the same time upregulate their TR6
expression by an as yet non-elucidated mechanisrn; TR6 secreted by these malignant cells
protect them from apoptosis and help them to evade immune surveillance; these ceils gain
survival advantages and eventually develop into tumors. In this scenario, TR6 by itself does
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flot cause the tumor, but functions as a tumor facilitator. Additional study is warranted to
prove this hypothesis.
111.5. The signficance ofozir study
We explored the biological function of TR6 and reveaied previously undocumented features
of this molecule in the immune system. We are the first to demonstrate the reverse signaling
property of TR6 through its ligand(s). In this case, its ligand LIGHT functions like a receptor
and transduces signais into LIGHT-expressing T celis upon TR6 ligation. Reverse signaling
through LIGHT aliows HveA-expressing T ceils to stimulate LIGHT-expressing T ceils, and
such two-way stimulation provides a theoretical base for T-cell-T-cell cooperation, which is
not a well-studied aspect of T-cell biology. The application value of this finding is to use
soluble monomer TR6 to downregulate undesirable immune responses by blocking the two
way costimulation between HveA and LIGHT. We have indeed demonstrated that this can be
achieved in the in vivo mouse model of GVHD and allograft rejection, although other
mechanisms might also contribute to the observed immune downregulation.
111.6. Future perspectives
Several points are worth exploring further in TR6 studies. Using blocking studies, we have
demonstrated that the reverse signaling triggered by TR6 was mainly mediated by LIGHT,
although we cannot absolutely mie out the involvement of fasL, which is also able to
reverse-signal, or other so-far unidentified ligands of TR6 in this process. Using LIGHT and
FasL knockout mice will convincingly resoïve this issue.
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The fact that TR6 is upregulated in some types of tumor celis indicates the roles of TR6 in
facilitating tumorigenesis. Using the sensitive TR6 ELI$A as described in the third article,
we have found that serum TR6 is a very reliable parameter for tumor diagnosis, according to
a 1 94-patient clinical study. Currently, additional multicentre trials are under way to further
validate this test for routine clinical use. Using TR6 transgenic mice, we are in the process of
confirming the facilitator rote ofTR6 in tumorigenesis.
We have found that soluble TR6 in the mouse system can reduce GVHD and graft rejection,
but the effect was moderate. This might be due to the short haif-life of the TR6 (jroduced in
insect celis) used, and due to the existence of other costimulating pathways. Stable
monomeric TR6 in combination with other immunosuppressants might be more effective in
treating undesirable immune responses.
These additional basic and clinical investigations will enhance our understanding of the
intricate interactions between TR6, LIGHT, HveA, FasL, fas, DR3 and TL1A, and make the
“bad” molecule TR6 work for a good cause.
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Figure 2. Gastric cancer lymphocyte infiltration is inversely correlated to serum
TR6 levels. Human gastric cancer samples were stained with HE, and lymphocyte
infiltration was serni-quantified from grade 1 to 4.
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL )UAOCHUN WAN 120
ACKNOWLEDGEMENTS
I would like to express my sincere gratitude to my supervisor Dr. Jiangping Wu for lis
scientific guidance, encouragement and patience throughout this study and during my
preparation ofthis thesis.
I would like to thank ail of our collaborators such as Dr. Jun Zhang and coworkers in
Hurnan Genome Science Inc. for their support and collaborations.
I wouid like to thank Dr. Huifang Chan, Dr. Shijie Qi and other coworkers in their group
for the assistance in experiments related to transplantation; Dr. Alain Comtois for use of
imaging system and fluorescence rnicroscopy.
I would like to thank Dr. Hongyu Luo for her valuable help in many experiments and
inspiring discussion.
I would like to thank ail people working as a dynamic team in ouï laboratory for their
kindly help and encouragement.
I would like to thank ail peopie who helped me in different ways and contributed to this
work.
I would like to thank ail my friends and those who aiways support me with encourage and
love.
FinaÏly, I would like to thank ail of my family members for their understanding, patience,
and their great support and encouragement which are critically important for me to
compiete this study.
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL XIAOCHUN WAN 121
)
Q
